Drugs during Pregnancy: Dangerous Business—The Continued Movement to Provide Adequate Warnings for the Consumer by Newbert, David DeTar
Nebraska Law Review
Volume 62 | Issue 3 Article 4
1983
Drugs during Pregnancy: Dangerous
Business—The Continued Movement to Provide
Adequate Warnings for the Consumer
David DeTar Newbert
University of Nebraska College of Law
Follow this and additional works at: https://digitalcommons.unl.edu/nlr
This Article is brought to you for free and open access by the Law, College of at DigitalCommons@University of Nebraska - Lincoln. It has been
accepted for inclusion in Nebraska Law Review by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Recommended Citation
David DeTar Newbert, Drugs during Pregnancy: Dangerous Business—The Continued Movement to Provide Adequate Warnings for the
Consumer, 62 Neb. L. Rev. (1983)
Available at: https://digitalcommons.unl.edu/nlr/vol62/iss3/4
Comment
Drugs During Pregnancy:
Dangerous Business-The
Continued Movement to Provide
Adequate Warnings for the
Consumer
[The child] was born on June 9, 1979 with birth defects in both arms and
both legs. [Her] right arm is totally missing. Her left arm consists of a
single short segment of bone which tapers to a point. [Her] right leg con-
sists of an appendage less than one centimeter long which she can move
voluntarily. 1
1. Description of Anne Elisabeth Koller, a plaintiff in the controversial Bendec-
tin suit against Richardson-Merrell, Inc. Plaintiffs Memorandum of Law in
Opposition to Motion for Summary Judgment on the Issue of Causation at 8,
Koller v. Richardson-Merrell, Inc., No. 80-1258 (D.D.C. Dec., 1982). Bendectin
is a prescription drug manufactured by Richardson-Merrell, Inc. and sold in
the United States for the alleviation of nausea and vomiting during preg-
nancy. Id. at 10. The same product is sold under other names (not by pre-
scription but over-the-counter) in certain other countries such as the United
Kingdom. The ingredients found in Bendectin are sold over-the-counter in
the United States in other products such as Unisom, Vicks Formula 44, and
Nyquil. Doxylamine succinate, a major ingredient of Bendectin, was shown
in a 1982 FDA computer print-out to be present in nine over-the-counter prod-
ucts and 13 prescription products. Id. The plaintiffs in the Koller case claim
that Bendectin is a teratogen. Id. at 16. See infra notes 58-60 and accompany-
ing text. Bendectin was first marketed in 1956. Originally it contained three
ingredients: dicyclomine, an anti-spasmodic; dexylamine, an antihistamine;
and pyridoxine (vitamin B), which has antinauseant properties. The drug
was reformulated in 1976 to eliminate dicyclomine, which was found not to
add to the drug's effectiveness. 11 FDA DRUG BULTiN (March 1981). An
estimated 10-25% of the pregnant women in the United States receive pre-
scriptions for Bendectin, usually in the first trimester. Id.
By its own admission, Merrell Dow Pharmaceuticals, Inc. has observed
that since Bendectin's introduction to the American market, over 33 million
patients have successfully used the product. Mailgram from Merrell Dow
Pharmaceuticals, Inc. to pharmacists, (June 9, 1983). Yet, researchers and
clinicians in and out of government as well as Dr. William McBride, the world
renowned teratologist responsible for pointing the finger at thalidomide,
claim that Bendectin may be, for a variety of complex reasons, even more
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I. INTRODUCTION
The above description represents but a single life. It is, of
course, a tragedy for even one child to be born with a serious mal-
formation or abnormality. But the tragedy extends beyond the in-
dividual child and the child's family, affecting the community as
well.2 More than 250,000 infants with birth defects were born last
year in the United States.3 The thalidomide4 and DES5 disasters
focused America's attention on the damaging effects drugs have on
the unborn.
Certainly no one would quarrel with the assertion that the man-
insidious than thalidomide. "Bendectin, a possible low-grade teratogen, may
be more dangerous than thalidomide, a high-grade teratogen [because]:
Most teratogens remain unknown. They are mysterious but often devas-
tating assailants of our unborn children. They carefully guard their secrets,
almost mockingly beckoning us to find them out. T.H. Bleakley & J.D. Peters,
Bendectin, 16 TRLAL 56 (May 1980). Because of the lower incidence of terato-
genesis with Bendectin, a "false sense of security and safety in physicians,
resulting in even greater usage" is more probable. Id.
In its correspondence to pharmacists announcing the company's decision
to cease production of Bendectin worldwide, Merrell Dow Pharmaceuticals,
Inc. cited Bendectin as "a victim of these litigious times." Mailgram from
Merrell Dow Pharmaceuticals, Inc. to pharmacists (June 9, 1983). But, per-
haps the real reason behind the withdrawal of Bendectin can best be
summed up as relating to a realization on the part of Bendectin's manufactur-
ers that, "The best that can be said.., is that there is no scientifically valid
proof which shows Bendectin to be safe... ." T.H. Bleakley & J.D. Peters,
Bendectin, 16 TRLu 56, 61 (May 1980). For an interesting discussion of the
controversy surrounding the Koller case, see Lauter, Bendectin Trial Disinte-
grates, NAT. L.J., Feb. 21, 1983, at 1. See infra notes 195-200 and accompanying
text.
2. The Nebraska Legislature recognized this fact when it enacted '"e Birth
Defects Prevention Program" in 1972. The "occurrence of malformation or
inherited disease at the time of birth is a tragedy for the child, the family, and
the community, and a matter of vital concern to public health." Neb. LB 1203,
82d Leg., 2d Sess., 1972.
3. By the age of one year, 5-6% of the children born in the United States are
recognized as having some sort of birth defect. Hutchings, Neurobehavioral
Effects of Prenatal Origin: Drugs of Use and Abuse, in DRUG AND CHEMICAL
RisKs To THE FETus AND NEwBoRN 111 (1980). This percentage means that
250,000 defective children are born each year in the U.S. Id. See NATONAL
FoUNDATION MARCH OF DnWEs, FAcTs/1983 at 2 (1983).
4. See iqfra notes 55, 73, 87, & 198-99 and accompanying text.
5. From 1947 to 1971, physicians prescribed diethylstilbestrol (DES) to millions
of pregnant women after the FDA had approved the use of DES to prevent
miscarriages in 1947. Bichler v. Eli Lilly & Co., 79 A.D.2d 317, 321-22, 436
N.Y.S.2d 625, 628-29 (N.Y. App. Div. 1981), aO'd, 450 N.Y.S.2d 776, 780-81 (1982).
Many daughters of these women have developed vaginal and cervical cancer
which has been linked to their exposure to DES (a synthetic form of the nat-
ural female hormone estrogen) in utero. See infra notes 221-22 and accompa-
nying text.
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ufacture of "over-the-counter" 6 and prescription drugs is big busi-
ness in the United States.7 Literally billions of prescription and
nonprescription drugs are sold each year in this country.8
Thousands of drugs espousing cures for every malady from the
common cold to constipation are offered to the public. But what
should consumers expect when they purchase and use these prod-
ucts? Should the manufacturer warn the consumer that certain
side effects may sometimes accompany the cure? How should
warnings be communicated?
The last two decades have seen a concerted effort on the part of
the courts and government to deal with these complex questions.
Recently, the Food and Drug Administration (FDA)9 amended the
general drug labeling provisions so as to include warnings on nu-
merous over-the-counter drugs.O These changes are directed at
protecting consumers who are either pregnant or nursing their in-
fants." As a result, manufacturers of thousands12 of over-the-
counter drug products will have until December 5, 1983 to comply
with the new labeling requirements.13
This Comment will briefly review the scientific information
which led to the new labeling requirements and give a historical
perspective of the government's role in protecting the American
consumer from dangerous drugs. This article will also explore the
drug manufacturer's role in the entire process and examine the
6. The term "over-the-counter" (OTC) derives from the basic marketing predi-
cate that nonprescription drugs are purchased over-the-counter by consum-
ers for the purposes of self-medication, typically without any intended or
actual intervention by a physician. See, e.g., Torsiello v. Whitehall Laborato-
ries, Etc., 165 N.J. Super. 311, 398 A.2d 132 (1979).
7. In 1980 the world market for pharmaceuticals was $75 billion, of which $22
billion was captured by firms headquartered in the United States. Drugs:
Questions and Answers, 37 FOOD DRUG COsM. L.J. 82 (1982). There are an
estimated 350,000 over-the-counter drugs on the market. Henteleff, OTC--a
Privileged Class, 36 FOOD DRUG CosM. LJ. 332, 339 (1981).
8. In 1973 alone, 2.8 billion prescriptions and drug orders were dispensed in this
country. Rucker, Drug Use, 229 J. A.M.A. 888-90 (1974).
9. For a discussion of the FDA's role, see infra notes 165, 182 & 185-87 and accom-
panying text.
10. Amendments to General Drug Labeling Regulations, 47 Fed. Reg. 54,750
(1982) (to be codified at 21 C.F.R. §§ 5.31(d), 201.63 and 330.2).
11. Id. For the warning language and a discussion of the new provisions, see in-
fra notes 297-329 and accompanying text.
12. FDA spokesman Ed Nida stated that as many as 300,000 products may be af-
fected by the new warning. Omaha World Herald, Dec. 3, 1982, at 4, col. 3. The
FDA already requires certain types of nonprescription drugs to carry specific
label warnings about their use by pregnant or nursing women. Id. These
special warnings, based on scientific information which suggests that the
drug(s) may pose a potential danger to developing or newborn children, will
not be affected by the new requirement. Id.
13. See 21 C.F.R. § 201.63.
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various tort liability theories involved. Finally, this Comment will
analyze the new federal regulations, including their potentially un-
welcome side effects.
I. BACKGROUND: THE PROBLEM
"We are living in a sea of chemicals that have not been tested
for their ability to cause cancer or birth defects."14 From a medical
standpoint, we truly are living in the era of the drug. In no other
society are therapeutic drug products so plentiful, so faithfully
used by the consumer, and so widely prescribed and recom-
mended.'5 New drugs appear on the market at an unprecedented
rate, far faster than the medical profession can possibly digest all
of the information about them.16 Almost every day brings news of
still another drug, once thought to have been useful as well as safe,
that has instead proved to be either worthless or lethal. It is not
known how many deaths occur each year in the United States as
the result of adverse drug reactions.' 7 Likewise, precise statistical
data revealing the number of malformations caused by drugs are
not available. Studies do suggest staggering figures-in the tens of
thousands for the former,18 and in the hundreds of thousands for
the latter. 9
14. Slone, Shapiro & Mitchell, Strategies for Studying the Effects of the Antenatal
Chemical Environment on the Fetus, in DRUG AND CHEMICAL RisKS TO THE
FETUS ANm NEWBORN 1 (1980) [hereinafter cited as Antenatal Chemical].
15. Merrill, Compensation for Prescription Drug Injuries, 59 VA. L, REV. 1, 2
(1973).
16. Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability, 18
RUTGERS L. REV. 947 (1964).
17. An adverse drug reaction is defined as a "noxious and unintended" response
"which occurs at doses used in man for prophylaxis, diagnosis or therapy."
Bennett & Lipman, Comparative Study of Prospective Surveillance and Vol-
untary Reporting in Determining the Incidence of Adverse Drug Reactions, in
TEXTBOOK OF ADVERSE DRUG REACTIONS 1 (D. Davies ed. 1977). The Code of
Hammurabi declared over 4,000 years ago that a physician who caused the
death of a patient should suffer the loss of his hand. Id. For an insightful
discussion of drug manufacturers' liability for unforeseen adverse drug reac-
tions, see Note, The Liability of Pharmaceutical Manufacturers for Unfore-
seen Adverse Drug Reactions, 48 FoRDBim L. REV. 735 (1980) [hereinafter
cited as Adverse Drug Reactions ].
18. Some suggest as many as 140,000 deaths from adverse drug reactions (among
hospital patients alone) occur each year. See Talley & Laventurier letter, 229
J. A.M.A. 1043 (1974). HEW's National Health Services Research Center esti-
mates that 1.5 million hospital admissions a year are due to adverse drug re-
actions. 14 P.M.A. NEWSLETTR, Dec. 21, 1972, at 3. In addition to the physical
effects measured in terms of human life and suffering, estimates of the mone-
tary cost of adverse drug reactions range from one to four-and-one-half billion
dollars per year (one-seventh of all hospital days). Adverse Drug Reactions,
supra note 17, at 737.
19. These figures are the combination of the oft-accepted figure of 250,000 chil-
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Biologists generally agree that the human embryo is suscepti-
ble to many outside factors.20 The naive belief that the fetus was
somehow protected from environmental influences and thus safe
within the mother's womb is obsolete. It is remarkable, though,
that prior to 1941, little credibility was given to the notion that envi-
ronmental factors might cause malformations to develop in the
human embryo.2 1 Unfortunately, although the dangers of so-called
"ethical drugs"2 2 are well-documented throughout society,23 a com-
placent belief continues to exist that over-the-counter drugs are
harmless. This belief, especially if held by pregnant or nursing wo-
men, is both naive and potentially tragic.
A. "Drugs"
One relatively common over-the-counter drug is acetylsalicylic
acid, an analgesic (pain killer) classified as one of the safest of
drugs.24 Approximately 15,000 tons of acetylsalicylic acid are pro-
duced and consumed in this country each year.25 A former Com-
missioner of Food and Drugs asserted, "There is no such thing as
dren born with birth defects each year and one authority's estimate that
about 10% of all birth defects can be attributed to known environmental fac-
tors (including drugs). J. WILSON, ENVIRONMENT AND BIRTH DEFECTS 49
(1973). Of course, this is not a maximum. Wilson estimates that the cause of
fully 65% of malformations is still unknown. Id. See infra notes 61-72 and
accompanying text.
20. Antenatal Chemical, supra note 14, at 1.
21. Id. In 1941, N.M. Gregg's classic demonstration showed that rubella infection
of women during pregnancy could cause severe malformations in their off-
spring. Id. But it was widely assumed by biologists and medical practition-
ers through the 1950's that the developing mammalian fetus was protected
from harmful environmental factors by the placenta. J. WILSON, ENVIRON-
MENT AND BIRTn DEFECTS (1973). The placenta was then believed to provide
an impervious shelter. Prior to 1960, the "placental barrier" was commonly
believed to effectively protect the human fetus from drugs given to the
mother. Id..
22. The term "ethical drug" may be used interchangeably with "prescription
drug" in contrast to over-the-counter medications. See supra note 6; see also
infra notes 266, 287-88 and accompanying text.
23. "It has been recognized that every drug is inherently dangerous and every
prescription drug has a potential for causing harm." M. DIXON, DRUG PROD-
UCT LIABLITY (1981 Revision). The Dixon text clearly and comprehensively
provides an excellent overview of the complex drug product liability area.
24. Better known as aspirin, it has been linked to adverse reactions, sometimes
serious and occasionally fatal. MALPRACTICE AND PRODUCT LiABIrrY ACTIONS
INVOLVING DRUGS 6-7 (R. Patterson ed. 1976). Suggestions that drugs contain-
ing aspirin should be available only by prescription and contain warning la-
bels have appeared recently. Weiss, Aspirin-A Dangerous Drug?, 229 J.
A.M.A. 1221-22 (1974).
25. Weiss, supra note 24, at 1222. Taken during pregnancy, aspirin has been asso-
ciated with unwelcome side effects for both the mother and her unborn child.
See infra note 34.
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absolute safety in drugs. There are some drugs that are less liable
to cause harmful reaction than others, but people die every year
from drugs generally regarded as innocuous." 26 This not too reas-
suring statement was made nearly twenty years ago and continues
to ring true today.
Drugs can be used for the prevention or cure of sickness and
disease, the diagnosis of conditions, the alleviation of symptoms,
and of course, the promotion of health. It is the chemical structure
of each drug that determines the way it will interact with and alter
the cells and chemicals of the body.27 Factors influencing the ef-
fect of a drug on the body include the body's ability to absorb, dis-
tribute, metabolize, detoxify, and excrete it as well as the
selectivity or "targeting" of the drug to a specific organ or site of
action.28 Direct action drugs may have one or more target organs.
Other drugs produce their effects on the target organ indirectly,
either by preventing another drug or chemical normally present in
the body from acting or by stimulating an organ which will in turn
affect target organs.29 The vast majority of drugs exert their effects
by modifying the metabolic activities of the body's cells.3 0 Since
drugs are chemicals, even if their specific therapeutic action is lim-
ited, they may produce nontherapeutic secondary reactions
throughout the body.31 In addition, many drugs on the market are
actually combinations of several different drugs or therapeutic
chemical elements. When taken together, one drug may enhance
the potency of the other or prevent the other's operation. Like-
wise, one element may bring the desired cure while the other ele-
ment causes an unwanted side effect. 32 In the case of
acetylsalicylic acid, the drug acts on the nervous system to relieve
26. George P. Larrick, Commissioner of Food and Drugs, 1961-66, Hearings on
Drug Safety Before the Subcomm. on Intergovernmental Relations of the
House Comm. on Government Operations, 88th Cong., 2d Sess., pt. 1, at 147
(1964) (quoted in Merrill, supra note 15, at 1).
27. DIXON, supra note 23, at 4-2.
28. Rheingold, supra note 16, at 950. Many drugs act directly to produce their
effects by stimulating "target" organs. Direct action drugs may have one tar-
get organ or many. For instance, aspirin acts on the nervous system to re-
lieve pain and reduce fever and on connective tissue in the joints to reduce
swelling. L GOODMAN & A. GnwAN, THE PHARmACOLOGICAL BASIS OF THERA-
PEU'ICs 327, 332 (5th ed. 1975).
29. See supra note 28.
30. DIXON, supra note 23, at 4-3.
31. Id.
32. Drugs that act by competing with other drugs or chemicals are called an-
timetabolites, antagonists, or blockers. Id. at 4-4. For a good discussion about
the side effects of drugs, see Rheingold, supra note 16, at 950-53. If, when
taken together, one drug enhances the potency of the other drug, the action is
synergistic; if the drug tends to prevent the operation of the other drug, it is
antagonistic in effect. Id. at 951.
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pain and on connective tissue in the joints to reduce swelling,33 yet
when the drug is taken during pregnancy, it has been associated
with unwelcome side effects for both the mother and her unborn
child.34
B. The Embryo and Fetus
The complexity of human development involves a staggering
100 billion bits of information.35 The development process is much
like a genetically preprogrammed series of instructions carried
within the structure of the DNA of the human egg.36 In the human
developmental program, the nine months prior to birth are the
most critical in the entire process. Most of the handicapping disor-
ders of infants and children are consequences of problems in pre-
natal development.3 7 Each year in the United States, some 1.2
million infants, children, and adults are hospitalized for treatment
and more than 62,000 persons of all ages die as a consequence of
birth defects. 38
Every human being begins life as a single cell. This cell (fertil-
ized egg) will grow and develop into a normal human being if con-
ditions in the womb (environment) are favorable. The
development of an unfertilized egg, however, begins much earlier
33. GOODMAN, supra note 28, at 327, 332.
34. Reports have associated the following defects with aspirin consumption: con-
genital heart disease, mongolism, congenital dislocation of the hip, hydrocele,
talipes, and papilloma of the forehead. Hays, Teratogenesis: A Review of the
Basic Principles With a Discussion of Selected Agents: Part II, 15 DRUG IN-
TELLIGENCE AND CLiNcAL. PHARMACY 542, 548 (1981). Another study found
that aspirin was associated with an increased length of gestation, post-matur-
ity syndrome, and increased duration of labor. Id. at 548. There have been
reports of neonatal bleeding problems in infants whose mothers consumed
aspirin shortly before delivery; one case required a transfusion for the infant
Id. Additionally, it has been shown that women who consume aspirin close
to delivery have an increased incidence of blood loss. Id. Aspirin has also
been shown to be a teratogen in animal studies. Id. at 550. What makes these
reports and statistics about the "common" (over-the-counter) aspirin alarm-
ing is the fact that approximately 80% of mothers ingest aspirin some time
during pregnancy! Id. at 548. See infra text accompanying notes 76-90.
35. Goldman, Critical Periods of Prenatal Toxic Insults, DRUG AND CHEMICAL
RISKS TO THE FETUS AND NEWBORN 9, 13 (1980).
36. Id.
37. Smith, Alcohol Effects on the Fetus, in DRUG AND CHEMICAL RISKS TO THE FE-
Tus AND NEWBORN 73 (1980). See infra notes 38-44 & 49-57 and accompanying
text.
38. NATIONAL FOUNDATION MARCH OF DiMEs, BIRTH DEFECTS: TRAGEDY AND HOPE
(1977). In addition, another half-million potential lives are destroyed each
year as the result of miscarriage and stillbirth-largely the consequence of
faulty fetal development. Id. A birth defect is an abnormality of structure,
function or metabolism. It may be genetically determined or the result of
environmental influence on the unborn child. Id..
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in the mother's ovaries while she herself is a fetus.39 The nine-
month span between fertilization of the egg and birth is an incredi-
bly complicated and fast-paced period of human development.
With the exception of identical twins, the genetic potential and en-
vironment of every individual during this period is different from
that of all others. The environment will continue to interact with
the preprogrammed set of genetic instructions throughout the en-
tire development of the egg.40
The embryonic stage of development commences during the
second week after conception and continues until the end of the
eighth week.4 ' It is during this time that the critical period for con-
genital malformations occurs.4 2 The development of the embryo is
most easily disturbed during organogenesis. 4 3 As the organs grow,
their susceptibility to structural damage from outside influences
decreases. But each organ has a critical period during which for-
mation may be deranged.44 The three major variables causing
nongenetic malformation include the type and amount of outside
influence in conjunction with the timing of the interference.45
The distinction between an "embryo" and the "fetus" occurs at
about sixty days following conception.4 6 By this time, the begin-
nings of all major structures are present. The fetal period extends
from approximately eight or nine weeks until birth and is primar-
ily a time of fetal growth. The growth rate greatly accelerates, with
tremendous weight gain during the final months prior to birth.
During this period many organ systems develop further, although
developmental changes are not as dramatic as throughout the em-
bryonic stage.47
39. Goldman, Critical Periods of Prenatal Toxicity, in 6 CuIcs IN PERINATOLOGY
203, 204 (1979).
40. See supra notes 35-36 and accompanying text.
41. DIXON, supra note 23, at 4A-11.
42. Goldman, supra note 39, at 207; DIXON, supra note 23, at 4A-11.
43. There exists a critical period of greatest teratogenic susceptibility for the em-
bryo which corresponds to the first trimester, which is when organogenesis
occurs. It is, therefore, "during the first three months that the major anatomi-
cal malformations may be induced." Hays, supra note 34, at 543. See DIXON,
supra note 23, at 4A-15.
44. DIXON, supra note 23, at 4A-15. For instance, the number of weeks from con-
ception of greatest susceptibility for certain organs are as follows: heart-
2%-5k; external genitalia-7-9; arms and legs---3 -7; ear---3-8%; central ner-
vous system--3-5; and eyes-3 -7%. Id.
45. See infra notes 54-58 and accompanying text. See also Hays, supra note 34, at
543. Of these external variables, timing is the most important. Id. See
Goldman, supra note 39, at 203.
46. Shepard & Fantel, Embryonic and Early Fetal Loss, in 6 CNcs IN PER-
NATOLOGY 219 (1979). The term "embryo" is reserved for the conceptus un-
dergoing organogenesis. Id. See supra notes 42 & 43 and accompanying text.
47. DIXON, supra note 23, at 4A-11.
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Prior to 1960, it was widely assumed by medical practitioners
and biologists that the placenta protected the developing fetus
from harmful environmental factors.48 The placenta, the mem-
brane which surrounds the fetus, was believed to provide an im-
pervious, shelter, a "placental barrier."49 As a result, it was
commonly believed that the placental barrier would effectively
protect the human fetus from drugs taken by the mother. This be-
lief was consistent with the widespread view that birth defects
were the result of maternal and paternal genetic traits. Today, the
placenta is known to act instead as a sieve and not as a barrier.
One noted commentator has observed, "Mothering before birth
is direct mothering."50 This is not difficult to understand when one
realizes that most chemical agents taken by the mother are also
"taken" by the fetus.5 1 The placenta operates as a bridge between
the fetal and maternal circulatory systems. All nutrients, oxygen,
and waste products cross this bridge. Thus, part of everything that
a mother ingests during her pregnancy reaches the developing life
within her. Once a drug has crossed the placenta, it enters the fe-
tal circulation system. Children have been born with the smell of
alcohol on their breath as well as with blood alcohol levels high
enough to be considered legally intoxicated.52 The major mecha-
nism by which drugs cross the placenta is passive diffusion.53 The
placental membrane becomes progressively thinner during preg-
nancy, thereby decreasing diffusion distance.
Embryotoxicity is defined as a disturbance of the embryonic
and/or fetal development by chemical dose levels which do not ad-
versely affect the mother.54 The presence or absence of toxicity in
the mother is not a reliable indicator for embryotoxicity. Toxic
agents which are completely harmless to the mother may prove
devastating to the embryo.55 This is primarily because the embryo
has a higher susceptibility to drugs than has the adult, due in part
48. Id. at 4A-6.
49. Id. See -upra note 21.
50. Smith, supra note 37, at 73.
51. Id.
52. Hays, supra note 34, at 546.
53. Id. at 542.
54. DIXON, supra note 23, at 4A-31, n.52. See infra note 55.
55. The "classic" human teratogen is thalidomide. Thalidomide was a safe and
nontoxic sedative when administered to nonpregnant recipients. DIXON,
supra note 23, at 4A-39. In fact, several suicide attempts with thalidomide
were unsuccessful with no apparent ill effects. Id. But thalidomide produced
severe phocomelic-type (affecting the arms, legs) defects in offspring of wo-
men when the drug was administered during the susceptible period of limb
organogenesis. Id. at 4A-38. See Goldman, supra note 45, at 203. It has been
reported that virtually every drug can be shown to be embryotoxic when ad-
ministered in the right dose at the susceptible stage of embryonic develop-
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to the particular vulnerability of certain embryonic cells that are
not found in corresponding adult cells.5 6 Another factor relates to
the sheer differences in dosage effect. A drug targeted at the 1,200
gram brain of the adult mother could have a much different effect
on the developing embryo, whose brain weighs less than a gram
during its most vulnerable stage of development. 7 A drug or other
agent which, when administered during pregnancy, is capable of
producing a structural malformation present at birth or a func-
tional defect in the offspring (including psychological or behavioral
alterations) either at birth or in the immediate postnatal period, is
known as a teratogen.58
C. Teratogens and Birth Defects
"Birth defects due to teratogens have a special poignancy-they
cause suffering to the most innocent of the innocent."5 9 Unfortu-
nately, the search for drugs which are teratogens is both a complex
and most difficult one. There exists neither compelling evidence
for nor against classifying the vast majority of drugs as ter-
atogens. 60 Numerous variables account for this lack of knowledge.
Birth defects6l represent an intricate interplay of genetics and
ment. J. WILSON & F. FRASER, 1 HANDBOOK OF TERATOLOGY 60 (1977). See
infra notes 80-82 and accompanying text.
56. DIXON, supra note 23, at 4A-34.
57. See Senfi, Woe Unto the Children, 17 THE NEB. TRAIscRi'r 21 (1982).
58. DIXON, supra note 23, at 4A-3. Teratology is defined "as the biological study
of the production, development, anatomy, and classification of monsters
(from the Greek teras')." Id. at 4A-4. Perhaps the oldest record of a congeni-
tal monstrosity is a marble statuette thought to date from 6500 B.C. showing a
body with two heads. Id.
59. Antenatal Chemical, supra note 14, at 6.
60. Oakley, Drug Influences on Malformations, in 6 CuIcs IN PERiNATOLOGY 403
(1979). Drugs may usually be placed in one of the following broad categories
according to their teratogenic risk. (1) knoum human teratogen-incidence
from exposure known by gestational time and dosage, or incidence from ex-
posure unknown but estimate of incidence after exposure; (2) suspected
human teratogen-reasonable estimate of maximum incidence after expo-
sure, or no reasonable estimate of maximum incidence after exposure; or
(3) not suspected to be a human teratogen-well-studied, minimally studied,
or no systematic studies; lower animal studies suggest mutagenesis or terato-
genesis. Id. at 406. See infra notes 62-72 and accompanying text; supra note
19.
61. See supra note 38. Birth defects may be classified as follows: (1) malforma-
tions present at birth, such as open spine, cleft palate, club foot, and numer-
ous other physical abnormalities; (2) inborn errors of metabolism (body
chemistry), such as cystic fibrosis, muscular dystrophy, juvenile diabetes,
and other diseases arising from the body's inability to produce a particular
enzyme or to convert certain chemicals into other chemicals; (3) blood dis-
eases, including sicklecell anemia, hemophilia, and others resulting from a
reduced or missing blood component; (4) chromosomal abnormalities such as
1983]
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environment. One frequently quoted scientific study found that
the cause of fully 65 percent of all malformations is unknown,
while 25 percent may be due to genetic and chromosomal factors.62
Only about 10 percent of the malformations could actually be at-
tributed to known environmental factors.63 These figures obvi-
ously do not mean that only 10 percent or less of all birth defects
are caused by drugs, nor should they be interpreted to imply that
75 percent of all birth defects are caused by unknown teratogens.
These statistics are merely indicative of the serious lack of recog-
nizable data on the problem of identifying the causes of malforma-
tions, spontaneous abortions, and stillbirths. It is generally
assumed that as many as 25 percent of all human pregnancies end
in spontaneous abortion,6 4 with the majority occurring during the
first trimester.65 Yet, one should bear in mind the fact that studies
arriving at the 25 percent figure have considered only those recog-
nizable pregnancies which survived through the implantation of
the egg and caused a missed menstrual period.66 There can be a
considerable time lapse before a woman realizes she is pregnant.
During this time, the delicate process discussed earlier is already
well underway.67 When perinatal death68 occurs, it is often unex-
plained. Because the frequency of abnormalities and malforma-
tions is perhaps ten times higher among abortuses than newborn
infants, spontaneous abortion is believed to be nature's selective
elimination process. 69 If a teratogen strikes early in the process
Down syndrome (formerly called mongolism); and (5) perinatal high-risk
conditions, including markedly low birth weight, often accompanied by hypo-
glycemia (low blood sugar level). Underweight newborns have a higher
death rate because of problems with breathing, heart action, digestion and
resistance to infection. NATIONAL FOUNDATION MARCH OF DIMES BIRTH DE-
FECTS: TRAGEDY AND HOPE at 3, (1977).
62. J. WSON, ENvmOiNmENT AND BIRTH DEFECTS 49 (1973).
63. Id. "Every observed association between drug exposure and a birth defect
represents only one of two possibilities: a cause and effect relationship or a
coincidental association occurring by chance alone without any causal rela-
tionship to drug exposure." DIXON, supra note 23, at 4A-69. "Distinguishing
between these two possibilities is often exceedingly difficult .... Id.
64. Shepard & Fantel, supra note 46, at 219.
65. Id.
66. Id. at 220.
67. See supra notes 42-44 and accompanying text.
68. "Perinatal" medicine focuses on the care and protection of the unborn and
the newborn from soon after conception through the first month of life.
"Death" in this context means the destruction of the life before birth as well.
Driscoll, Placental Lesions, in 6 CLnIcs IN PERINATOLOGY 397, 398 (1979).
69. Shepard & Fantel, supra note 46, at 222. Preterm and stillborn infants have
significantly higher rates of congenital malformations. But approximately 75
percent of structurally abnormal embryos and fetuses never reach the viable
stage. Id. at 225.
[Vol. 62:526
DRUGS DURING PREGNANCY
causing the death of an embryo,70 the resulting spontaneous abor-
tion may very likely be attributed to nature's plan as well. The fact
is in most instances, structural defects, whether genetic or envi-
ronmental, are morphologically identical.7' A particular teratogen
can produce a variety of birth defects that may arise singly or as a
syndrome. Due to this lack of specificity it becomes difficult to es-
tablish an unambiguous causal relationship in humans.72 The ter-
atogenicity of thalidomide was discovered only because it
produced such a rare syndrome of defects.7 3 More recently, alcohol
has been identified as a teratogen for the same reason.74 This led
one commentator to suggest that if thalidomide--or even aspirin-
produced a more common type of defect, like cleft palate in per-
haps 5 percent of the cases in which it was consumed in the first
70. See supra note 68.
71. Hutchings, Neurobehavioral Effects of Prenatal Origin: Drugs of Use and
Abuse, in DRUG AND CHEMiCAL RISKS TO THE FETus AND NEWBORN 108, 111
(1980). See supra notes 64-73 and accompanying text. In addition, a ter-
atogen tends to give rise to a spectrum of defects, a spectrum that may vary
greatly both in extent and severity. Smith, supra note 37, at 74. Another
problem is that a teratogen seldom causes defects in 100% of exposed fetuses.
Id.
72. Hutchings, supra note 71, at 111.
73. Id. The evidence implicating thalidomide as a teratogen is now overwhelm-
ing, but no evidence of teratogenic effect was seen when thalidomide was
tested on certain animals prior to release for clinical use. 0. HEINONEN, D.
SLoNE & S. SHAPYRo, BirTH DEFECTS AND DRUGS IN PREGNANCY 2 (1977). In
pregnant women, exposure to even a single dose, from the twentieth to the
thirty-fifth day after conception produced a unique syndrome characterized
principally by deformities of the arms, legs and face, often together with more
widespread deformities. Id.
74. Hutchings, supra note 71, at 111. Actually the serious impact of alcohol in
fetal development was independently implied in 1834, in the 1880's and the
early 1900's. Smith, supra note 37, at 75. "Behold, thou shalt conceive, and
bear a son; and now drink no wine or strong drink.. . ." Judges 13:7. Thus,
over two thousand years ago a link between birth defects and alcohol was
recognized. The "fetal alcohol syndrome" (FAS) was first associated with
heavy alcohol consumption, but later studies have shown an increased risk
with moderate alcohol consumption as well. Hays, supra note 34, at 546. The
defects in FAS can be divided into four major groups: (1) central nervous
system dysfunction; (2) growth deficiency; (3) characteristic facies; and
(4) associated anomalies. Id. FAS children often have defects which are
manifested in one or more of the following areas: (1) cardiac-murmurs, es-
pecially in early childhood; muscular-hernias of diaphragm and groin;
(2) nose-short-upturned; (3) central nervous system-mild to moderate
mental retardation in over 80 percent of the cases; (4) mouth-small teeth
with faulty enamels, cleft lip or cleft palate; and (5) eyes-short palpebral
fissures; and marked growth deficiency. Id. at 548. Besides long-term
problems, FAS infants face the possibility of acute alcohol withdrawal at
birth manifested by seizures, irritability, hypoglycemia, and tremors. Id. at
546.
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trimester, it would probably not have been suspected.7 5 Attempts
have been made to establish a relationship between prenatal drug
exposure and later neurobehavioral impairments. There is strong
evidence which indicates that some impairments such as gross
structural defects are of genetic origin but can also be produced by
early exposure to environmental agents.7 6 Whether genetic or en-
vironmental, the symptomatology is virtually identical.7 7 One good
example is hyperactivity. Genetic factors have been implicated as
playing a significant role in the hyperkinetic syndrome,7 8 but this
same behavioral impairment has also been reported in children
following prenatal exposure to alcohol and cigarette smoke.7 9 The
products of cigarette smoking-nicotine, carbon monoxide, and cy-
anide have also been linked to an increased spontaneous abortion
rate, decreased birth weight, and mental retardation in the surviv-
ing offspring.80 In addition, the infants of mothers who smoke
were shown to experience a direct dose-response relationship be-
tween the amount smoked and the level of nicotine in the mothers'
breast milk.81 Mental retardation is common with fetal alcohol
syndrome offspring.82
Frequently, multiple drugs are administered during pregnancy.
One study found that a woman may take from three to twenty-nine
drugs while pregnant, including labor and delivery medication,
with ten being the average number.83 As a result, it becomes very
difficult to isolate the teratogen that may have induced an abnor-
mality. A woman who has had a baby born with a birth defect has
probably pondered in great detail the events and stages of her
pregnancy, looking for an explanation. Women who bear normal,
healthy children seldom do such reflecting.
Research on the effects of drugs on animals is often used to
75. See A. BARNES, INTRA-UTERINE DEVELOPMENT 362-77 (1968).
76. Hutchings, supra note 71, at 111.
77. Id.
78. Id. See DIXON, supra note 23.
79. Hutchings, supra note 71, at 111-12. See infra notes 80 & 81.
80. Witter & King, Cigarettes and Pregnancy, in DRUG AND CHEMICAL RISKS TO
THE FEus AND NEWBORN 83, 89-90 (1980). Smoking exposure in utero may
have a long-term effect on both the physical health and mental function of the
offspring. Id. Observed defects include: increased fetal heart rate; decreased
fetal breathing movements; decreased IQ; increased incidence of sudden in-
fant death syndrome; increased neonatal mortality; decreased head circum-
ference; decreased post-natal growth; increased behavioral disturbances; and
decreased length at birth. Hays, supra note 34, at 565. Such dangers have
prompted Congress to consider new, stiffer label warnings on cigarettes. See
infra note 334 and accompanying text.
81. Witter & King, supra note 80, at 89.
82. Hays, supra note 34, at 546. See supra note 74.
83. Id. at 545.
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elicit data which can be applied to predict which substances will
likely be harmful to the developing human fetus.84 However, such
findings are not always conclusive. As one leading experimental
teratologist observed, "A drug that is not demonstrably teratogenic
in experimental animals may be so in man. A drug that is demon-
strably teratogenic in animals may not be so in man. Therefore,
the final proof of whether a drug is likely to be teratogenic in man
must be sought in man."8 5 But even this less-than-encouraging ob-
servation may be somewhat misleading, for the impact of a given
teratogen can seldom be predicted from its effects on the mature
individual.86 Although considered a "classic" human teratogen,
thalidomide was a safe and nontoxic sedative when administered
to nonpregnant recipients.87 In addition, surveillance of drugs for
their damaging effects on the human fetus is not readily accom-
plished through voluntary reporting by physicians.88 As noted ear-
lier,8 9 unless a striking and rare abnormality is observed in
association with an administered drug, physicians will most proba-
bly be unaware of the resulting defects. Finally, the delayed ef-
fects of drugs on humans following intrauterine exposure must
also be considered. DES was found to lead to a high incidence of
vaginal carcinoma in humans, but fifteen to twenty years were re-
quired for the effect of the intrauterine exposure to be evident.90
The socio-medical aspects of the problem can thus be cap-
sulized as follows: Drugs have become an almost subliminal part
of everyday life for millions of American women, with many sim-
ply assuming that nonprescription, over-the-counter drugs are, by
their very nature, safe; yet, the unborn life carried within each
84. DixoN, supra note 24, at 4A-21, 4A-22.
85. Id. at 4A-20 (quoting F.C. Fraser) (emphasis added).
86. See supra notes 71-73, 76, 77 & 85 and accompanying text; see infra notes 87-88
and accompanying text.
87. See supra note 55; infra notes 196-99 and accompanying text.
88. Freeman & Finkel, Drug and Other Hazards to the Fetus and Newborn, in
DRUG AND CHEMICAL RISKS TO THE FETus AND NEWBORN 67, 69 (1980).
89. See supra notes 73-75 and accompanying text.
90. Yaffe, Summary: Pediatrician's View, in DRUG AND CHEMICAL RISKS TO THE
FETus AND NEWBORN 157, 158 (1980). It has also become apparent that some
male offspring were also affected, having abnormalities of the reproductive
system including epididymal cysts, hypotropic testes, and pathologic semen.
Id. Furthermore, cancer researchers in Boston have recently reported that
sons of DES mothers may be likely to develop testicle cancer. Study: Syn-
thetic Hormone May Produce 'DES Sons', LA Times Report published in
Omaha World-Herald, March 11, 1983 at 16, col 3. A great deal has been writ-
ten about the DES tragedy. Several comprehensive discussions include:
Abrahams & Musgrave, The DES Labyrinth, 33 S.C. L. REV. 663 (1982); Com-
ment, DES and a Proposed Theory of Enterprise Liability, 46 FORDHAM L.
Rv. 963 (1978); Note, Market Share Liability: An Answer to the DES Causa-
tion Problem, 94 HARv. L REV. 668 (1981).
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pregnant woman is exceedingly fragile and vulnerable to damaging
influences throughout every stage of development; much, much
more is unknown about the effects during pregnancy (both short-
and long-term) of thousands of drugs than is known. This brief
discussion of the effects of drugs on fetal development may be
helpful in gaining a better understanding of the motivating factors
which led to the promulgation of the new FDA warning regula-
tions. However, a historical look at the consumer's niche in the
food and drug marketplace may provide further insight.
M. HISTORICAL PERSPECTIVE: GOVERNMENT'S ROLE
AS CONSUMER PROTECTOR
[M] en with the muck-rake are often indispensable to the well-being of so-
ciety, but only if they know when to stop raking the muck.91
In 1810, the life expectancy of the average consumer living in
Boston was twenty-seven years. 92 In 1845, the average life expec-
tancy had fallen to only twenty-one years. 93 The first federal drug
law came three years later. The Import Drugs Act of 1848 was en-
acted to prevent the importation of adulterated drugs.9 4 But it
would take Congress another fifty-four years to pass a national
piece of drug legislation that would provide any protection for the
consumer.95 Unfortunately, the history of the government's role as
protector of the American consumer is "highlighted" by an on-go-
ing need for tragedy and scandal to serve as catalysts for congres-
sional action, with the courts themselves only occasionally rising
to the consumers' defense.
A. The Early Years: Government Apathy
In 1902, twelve children died as the result of ingesting a diph-
theria antitoxin.9 6 This tragedy spurred Congress to pass the
strongest drug control legislation it had ever enacted: the Bio-
91. Theodore Roosevelt, 1906 noted in Litman & Litman, Protection of the Ameri-
can Consumer. The Muckrakers and the Enactment of the First Federal Food
and Drug Law in the United States, 36 FOOD DRUG COSM. .J. 647, 649 (1981)
[hereinafter cited as Litman].
92. Hutt, Food and Drug Law: A Strong and Continuing Tradition, 37 FOOD
DRUG CoSm. L.J. 123 (1982).
93. Id.
94. Ch. 70, 9 Stat. 237 (1848). The Import Drugs Act of 1848 was our first federal
drug law and provided for laboratory inspections at ports of entry. Janssen,
Outline of the History of U.S. Drug Regulation and Labeling, 36 FOOD DRUG
COSM. L.J. 420, 423 (1981).
95. In 1902, Congress enacted the Biologics Act, ch. 1378, 32 Stat. 728 (1902).
96. Janssen, supra note 94, at 425. The St. Louis Health Department was con-
cocting its own diphtheria antitoxin when a tetanus contamination occurred.
Twelve children died and ten recovered. Id.
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logics Act.97 But during the 19th century, the only federal law that
could have been used against drug misbranding and quackery was
the first mail fraud statute, enacted in 1872.98 Yet, for nearly three
decades there was no record of its enforcement in the drug area.99
The federal government instead relied on a potpourri of state laws,
many dating from colonial times. Furthermore, most of these laws
were not consumer laws at all, but were enacted to serve the needs
of trade and business.100 After the Civil War, change from an agri-
cultural to an industrial economy made it necessary to provide the
rapidly increasing urban population centers with food from distant
areas.101 A boom in commercial food processing resulted and the
use of chemical preservatives such as formaldehyde, borax, and
salicylates became commonplace. In addition, artificial colors,
some toxic, were indiscriminately used. Labeling gave no hint as
to the dangerous ingredients employed. 0 2
During this period the United States, lacking the laws and regu-
lations of European countries,103 found its export market suffering
from the discredit cast upon American food and drug products.104
National inspection procedures abroad were so stringent and thor-
ough that the complete absence of any such standards in this
country was viewed as evidence of a disinclination on the part of
the federal government to protect consumers against commercial
avarice and fraud.l05 The apparent philosophy of government was
the old policy of caveat emptor-let the buyer beware. As a result,
advertising campaigns in industrial America encouraged consum-
ers to take patent-medicines without knowing what chemicals or
ingredients they were consuming. Most of the drugs were over-
the-counter preparations guaranteed to cure all manner of dis-
eases and ailments. Many were plainly worthless, but others were
often poisonous or addictive. 0 6 Poisonous "women's remedies"
were sold in amazing quantities, and the sum total of their harmful
effects will never be known. "Poor mothers doped their babies into
insensibility at night with soothing syrups containing opium, mor-
phine, cocaine, laudanum and alcohol."107
The organized patent-medicines industry wielded tremendous
97. Id. See supra note 95.
98. Janssen, supra note 95, at 424.
99. Id.
100. Id. at 425.
101. Id. at 421.
102. Id.
103. Litman, supra note 91, at 661.
104. Id.
105. Id.
106. Id. at 652.
107. Id.
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power over the press through its vast expenditures for advertising.
It was estimated that over $100,000,000 a year was paid to newspa-
pers and magazines to advertise patent-medicines.lOS And no won-
der, the profits were unbelievable. Many patent-medicines cost
about eight cents to produce and sold for a dollar.109 Furthermore,
many of these concoctions, containing water and sulphuric acid,
also contained a variety of habit-forming drugs. Thus, the "cure"
often continued to be in demand long after the patient's sickness
had subsided. In order to prevent adverse legislation, one drug
manufacturer inserted in its advertising contracts with over 15,000
newspapers this clause: "It is hereby agreed that should your
State, or the United States Government, pass any law that would
interfere with or restrict the sale of proprietary medicines, this
contract shall become void."110
How effective was the industry's attempt to block national legis-
lation that would protect the American public from dangerous and
worthless drugs? Between January 20, 1879 and June 30, 1906,
when the Pure Food and Drug Act"' was finally passed, 190 meas-
ures were presented in Congress which were designed in some
fashion to protect the consumer from adulterated and misbranded
food and drugs.112 Of the 190 bills introduced during this twenty-
seven year span, only eight became law." 3
B. The Battle of the Muckrakers
Four years before the passage of the 1906 Pure Food and Drug
Act, Dr. Harvey Wiley, a leading proponent for consumer drug leg-
islation, organized a "Poison Squad."114 Referred to by a commen-
tator as the "ultimate in human experimentation,"lls the Poison
Squad was comprised of twelve "young robust men" from the De-
partment of Agriculture who were placed on a regimented diet
containing many different food preservatives. 116 The experiments
were carried on for five years and conclusively proved that such
preservatives were indeed harmful." 7
108. Id. at 663.
109. Id. After 50 years, the drug industry's profits have apparently changed little.
See R. HARIus, THE REAL VOICE 59-63 (1964) (discussing 1,118 percent mark-
ups, and the selling of drug products for $8 that were purchased for 28c).
110. M. MUTZ, BY PRESCRITON ONLY 43 nA (1967). See infra note 121.
111. Ch. 3915, 34 Stat. 768 (1906).
112. Litman, supra note 91, at 661.
113. Id
114. Id. at 662.
115. Id.
116. Id.
117. Id. Lew Dockstader, a minstrel star of the times, introduced a song dedicated
to the poison squad with the refrain:
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As early as 1892, one magazine, the Ladies' Home Journal, had
denied its advertising pages to manufacturers of patent-
medicines.1 1 8 But it was not until over a decade later that the ef-
forts of Wiley, a group of journalists, and a novelist named Upton
Sinclair aroused the American consumer. While Wiley's Poison
Squad was making headlines and music," 9 a group of crusading
writers joined the campaign for consumer legislation. The journal-
ists became known as the "muckrakers"120 and shocked public
opinion with their editorials, articles, and cartoons which graphi-
cally described the fraud, high profits, and squalid conditions in
the industry.121 This publicity together with Sinclair's novel, The
Jungle,122 which horrified the American public with its sickening
depiction of the meat packing industry, finally provided Congress
with the necessary political prodding.
A Pure Food and Drug bill had sat in limbo on committee tables
for over twenty-five years without passage. It was the belated sup-
port of President Theodore Roosevelt that proved to be the chief
0, they may get over it but theyll never look the same.
That kind of bill offare would drive most men insane.
Next week he'l give them mothballs, a la Newburgh or else plain;
0, they may get over it but theyll never look the same.
Janssen, supra note 94, at 426.
118. Litman, supra note 91, at 663.
119. See supra note 117.
120. Numerous books and magazine articles decried the greed and lawlessness of
big business and the "venality of politicians." Litman, supra note 91. Upton
Sinclair most vividly "raked up the muck" in his novel The Jungle. See infra
note 122. 'The muckrakers advocated the pure food and drug legislation be-
cause it increased the protection of the public health, decreased the amount
of sickness, and lengthened the average American's life span." Litman, supra
note 91, at 655.
121. One of the worst abuses of the era was the addiction of babies to "soothing
syrups", often given to make them stop crying. There were at least a hundred
such products on the market, containing varying amounts of morphine,
opium, or heroin. Janssen supra note 94, at 428. The Chicago Tribune led the
fight against these "soothers", calling them "baby killers" instead. Id.
Charles Edward Russell excoriated the "beef trust" in Everybody's in articles
entitled 'Ie Greatest Trust in the World." Litman, supra note 91, at 648.
122. The Jungle told of the life of a Lithuanian peasant working in the Chicago
meatpacking establishments. Litman, supra note 91, at 665. Meant to serve
as propaganda for socialism, it was the information it revealed about the un-
healthy conditions prevalent in the packing houses as well as about the un-
clean meat which was regularly sold to the consumer that caught the public's
attention. Id. "Sinclair described how diseased cattle were butchered,
marked by the government inspectors, thrown into dumps, loaded on carts
and wheeled back again and mingled with other carcasses and treated and
sold as clean meat." Id. The author later observed that he had aimed at the
public's heart but by accident had hit the stomach. Such sensational
passages about the squalid conditions comprised only about eight pages out
of the 308 pages in The Jungle, but those eight pages horrified and outraged
the American consumer. Id.
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stimulus for final enactment of the bill.123 Roosevelt had not been
involved in the long struggle for the bill's passage until the surge of
public support and outrage caused by the muckrakers and The Jun-
gle.124 As a result of the scandal exposed by Sinclair's novel, a na-
tional meat inspection bill would have to be signed or the
politicians would have had to answer to their voting constituents.
The Federal Meat Inspection Act125 proved to be the catalyst
needed to get the Pure Food and Drug Act of 1906 passed.126 On
June 30, 1906, Roosevelt signed the original Pure Food and Drug
Act, which also became known as the Wiley Act.127
C. The Elixir Tragedy and the Act of 1938
It has been asserted that no single event has had greater signifi-
cance in the history of consumer protection laws or the industries
they regulate than the 1906 Act.128 The primary purposes of the
1906 Act were to prohibit misbranded, false, or misleading labels
on drugs,129 and to keep such drugs from being sold in interstate
commerce.130 These goals quickly proved to be ineffective. The
drug industry, having lost the twenty-seven year battle over the
enactment of the Act, wasn't about to concede the war and was
determined not to be bound by the new law. Various political ma-
neuvers were quickly designed to prevent strict enforcement of the
new law.131 As Wiley later observed, the drug industry "caused
long and agonized trouble. Having lost the fight in Congress, a
number of adulterators and misbranders sought to destroy the law
and prevent its enforcement."132 The 1906 Act also proved to con-
tain many serious loopholes 3 3 and the industry was quick to capi-
123. Id. at 668.
124. Id.
125. Ch. 3919, 34 Stat. 669 at 674 (1906).
126. Ch. 3915, 34 Stat. 768 (1906).
127. Janssen, supra note 94, at 420. See Litman & Litman, Protection of the Ameri-
can Consumer: The Congressional Battle for the Enactment of the First Fed-
eral Food and Drug Law in the United States, 37 FOOD DRUG COSM. UJ. 310
(1982). The 1906 Act was commonly referred to as the Wiley Act because its
enactment was largely the result of Dr. Harvey Wiley's (chief chemist of the
U.S. Dept. of Agriculture) efforts.
128. Janssen, supra note 94, at 420.
129. McClellan, Tate & Eaton, Strict Liability for Prescription Drug Injuries: The
Improper Marketing Theory, 26 ST. Louis U.L.J. 1, 14 (1981) [hereinafter cited
as Eaton].
130. Id.
131. Id. The politically appointed solicitor of the Federal Department of Agricul-
ture moved rapidly to prevent strict enforcement of the 1906 Act by diluting
Dr. Wiley's authority. Id.
132. Id.
133. The 1906 Act did not provide any control over advertising, as distinguished
from labeling of drugs. Mnmz, supra note 110, at 44. Neither did the 1906
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talize on them. 3 4 In addition, the United States Supreme Court
dealt a severe blow to the Act in 1911 in the first drug case to come
before the Court. In United States v. Johnson, 3 5 the Court inter-
preted the Act as prohibiting false and misleading claims as to the
ingredients of the drug but not as prohibiting false therapeutic
claims as to the curative properties of the drugs themselves. 3 6
Congress passed the Sherley Amendments 37 in 1912 to overrule
the Court's decision. The 1912 amendments specifically forbade
false and fraudulent therapeutic claims on the labeling of medicine
intended to defraud the purchaser. 3 8 This simple change in phra-
seology was observed to practically legalize false therapeutic state-
ments because, "to be illegal, they had to be both false and
fraudulent, a fact very difficult to prove [because fraud involves
intent to deceive]."139 The same commentator wrote that "the
phraseology was advocated at the hearings on the amendment by
Charles M. Woodruff at Parke-Davis and Company,"' 40 one of the
nation's largest drug manufacturers.
Dr. Wiley, in his autobiography, stated, "The trouble now is that
no one takes much interest in the Food and Drugs Act-that is to
legislation prevent use of an eyelash cosmetic that caused blindness nor the
use of thallium, which is now recognized as too hazardous even for consumer
use as rat poison. Id. at 48. The Act also did not require any form of
premarketing clearance by the government, so there was no reasonable
means available to prevent a product from being sold in interstate commerce
before it had been tested for safety. Eaton, supra note 129, at 15. See infra
note 136 and accompanying text.
134. See supra note 133. As a result, "Nostrum advertising boomed. The damage
to health, the waste of life, the squandering of money for worthless medica-
tions-all of these kept pace." Mn'rz, supra note 110, at 44.
135. 221 U.S. 488 (1911).
136. Id. at 497. Thus, in the case of "Dr. Johnson's Mild Combination Treatment
for Cancer," the promoter could not be prosecuted for "mistaken praise",
even though the indictment charged that he knew his claims were false. Id.
at 488 (notice of judgment no. 1058). Janssen, supra note 94, at 427. President
Taft immediately called on Congress to close this dangerous loophole in the
1906 law, saying-
There are none so credulous as sufferers from disease. The need is
urgent for legislation that will prevent the raising of false hopes of
speedy cures of serious ailments by misstatements of facts as to
worthless mixtures on which the sick will rely while their disease
progresses unchecked.
(Message from President Taft). 62 CONG. REC. 1st Sess. 2380 (June 21, 1911).
Congress passed the Sherley Amendments in 1912 to overrule the Johnson
Court's decision. See infra notes 137-38 and accompanying text.
137. Sherley Amendments to the Pure Food and Drug Act of 1906, ch. 352, 37 Stat.
416 (1912).
138. Eaton, supra note 129, at 15.
139. MnrNz, supra note 110, at 44 (quoting Stephen Wilson from the Food and
Drug Regulation). The Sherley Amendments were thus ineffective.
140. Id.
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say, no one in Congress. It is regarded as established and in per-
fect operation. This is a great mistake."141 Unfortunately, among
the public at large, the 1906 Act was also mistakenly thought to be
providing adequate protection. The economic hardships of the de-
pression years magnified the Act's many shortcomings.142 The
book, Your Money's Worth,143 signaled the start of a new world-
wide consumer movement.144 But it would take another tragedy
with the loss of over one-hundred lives to make Congress take
action.
In 1937, the Massengill Company marketed an "Elixir of
Sulfamilamide."145 The solvent was diethylene glycol, a chemical
relative of permanent radiator antifreeze. 4 6 The 1906 Act did not
require testing of the chemical before making it available to the
consumer. Massengill did not test the "Elixir" beyond checking it
for fragrance, appearance, and flavor.147 Of 240 gallons manufac-
tured, 113/ were distributed across drug counters with and without
prescriptions. With the first reports of deaths in October 1937,
seizure of the chemical immediately began and all but the 11 / gal-
lons that had been distributed were confiscated. 4 8 Ironically,
these seizures were possible only because the drug had been mis-
branded as an "Elixir," which wrongly implied that it contained
alcohol.149 Had the deadly mixture instead been called a "solu-
tion", the federal authorities could not have legally seized the
product. When it was all over, 108 persons were dead, including
the pharmaceutical chemist who had developed the drug; but un-
like the other victims, his death was a suicide. 50 Later testimony
revealed that by simply testing the drug on animals, the poisonous
danger of the Elixir would have been exposed to the manufac-
turer.'15 Again the public reacted with outrage. When Congress
finally addressed the need to overhaul the 1906 Act, thirty-two
years had elapsed.
Among the many important advances contained in the Federal
Food, Drug, and Cosmetic Act of 1938152 was a section which re-
quired manufacturers to test each new drug for safety and to re-
141. MnQrz, supra note 110, at 44.
142. Janssen, supra note 94, at 428.
143. S. CHASE, YOUR MoNEY's WORTH (1934).
144. Janssen, supra note 94, at 428.
145. Id. at 429. See Eaton, supra note 129, at 16. MINTz, supra note 110, at 48.
146. MiZ, supra note 110, at 48.
147. Id.
148. Id.
149. Id. at 49.
150. Id.
151. Id. at 48.
152. 21 U.S.C. §§ 301-392 (1976). The Act became effective on June 25, 1938.
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port the results to the Food and Drug Administration. 5 3
Unfortunately, as had been the case with its predecessor, the 1938
Act contained some large loopholes. For instance, unless the FDA
acted within 180 days to prevent marketing, a new drug could auto-
matically be sold to the consumer.1 5 4 The FDA was empowered to
delay the release of a drug even longer if it found that the manufac-
turer's test did not show the drug to be safe under recommended
conditions, and the agency was given authority to remove from the
market a drug it could prove to be unsafe.'5 5 But the 1938 Act also
contained a grandfather clause which exempted drugs on the mar-
ket prior to 1938 from the premarketing clearance procedures. 5 6
As a result, the stricter new provisions were applied solely to new
drugs to be sold in interstate commerce. The 1938 Act also failed to
require manufacturers to establish that their products were effec-
tive as well as safe for intended use.1 57 An efficacy requirement
had been proposed in the original 1933 bill,158 but Congress, in kill-
ing the consumer-oriented aspect "was, some contend, recognizing
the economic, lobbying and political--not the medical-facts of
life." 59 In any respect, almost thirty years would pass before the
FDA would be given specific authority to examine "new" drugs to
153. Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040, 1052 (1938),
amended by 21 U.S.C. § 355(b) (1976). The premarketing clearance proce-
dure required drug manufacturers to file new drug applications (NDA) with
the FDA. Id. See infra notes 203-09 and accompanying text.
154. Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040, 1052 (1938),
amended by 21 U.S.C. § 355(c) (1976). In addition, there still was no require-
ment that the manufacturer establish the efficacy of the product prior to mar-
keting. Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040, 1052
(1938). This was capitalized on by many manufacturers and led to the sale of
ineffective drugs, "allow[ing] the manufacturers to make exaggerated and
unsubstantiated claims about the efficacy" of their products. Eaton, supra
note 129, at 16.
155. Mnrz, supra note 110, at 49. See supra notes 152-54. Although many com-
promises had been made to secure passage of the 1938 Act, the new law did
provide some major improvements: proof of fraud was no longer required to
stop false claims for drugs; cosmetics and therapeutic devices were regulated
for the first time; specific authority was given for factory inspections; addition
of poisonous substances to foods was prohibited except where unavoidable
or required in production; federal court injunctions against violations were
added to the previous legal remedies of product seizures and criminal prose-
cutions; and, drug manufacturers were mandated to provide scientific proof
that new products were safe before putting them in the marketplace. Jans-
sen, supra note 94, at 429.
156. Eaton, supra note 129, at 17.
157. See infra notes 158-59 and accompanying text.
158. The "Tugwell Bill" introduced in Congress in 1933 "was a legislative disaster"
with "[t]he opposition of industry and advertising interests to this New Deal
legislation... total and overwhelming." Janssen, supra note 94, at 429.
159. Mnz, supra note 110, at 49 (emphasis added).
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determine whether or not these drugs produced the results prom-
ised by their manufacturers.160
D. Enter the FDA
Important pharmaceutical history resulted from section 502(f)
of the 1938 Act which required drug packages to be labeled with
adequate warnings and directions for proper use.161 However, the
Act exempted manufacturers from having to provide directions
when they were "not necessary for the protection of the public
health."162 The new statute fell far short of providing a clear, com-
plete, and workable system of drug labeling and regulation.163 Yet,
because the new Act was in such contrast to its 1906 predecessor,
many of the shortcomings of the 1938 statute were not apparent.
From 1906 until 1927, the Bureau of Chemistry enforced the
original 1906 Act.164 In 1927 the Food, Drug, and Insecticide Admin-
istration was formed and in 1931 renamed the Food and Drug Ad-
ministration.165 On December 28, 1938, the FDA published in the
Federal Register its general regulations for the enforcement of the
Federal Food, Drug and Cosmetic Act of 1938.166 Drugs whose
common uses were known to the ordinary individual were ex-
empted from labeling with "adequate directions."167 In addition,
drugs identified with what was soon to be called the RX Legend-
"Caution: to be used only by or on the prescription of a. . ." (phy-
sician, dentist, or veterinarian)-were also exempt.16 8 Further-
more, "all representations or suggestions" with respect to the uses
of these drugs were required to appear only in such medical terms
as are not likely to be understood by the ordinary individual."169
Shipments were to be made only "for use exclusively by or on the
prescription of physicians, dentists or veterinarians licensed by
law to administer or apply such drugs . .,,170 Distributions via
other channels would not be exempted, thus making the ship-
ments illegal.171 As a result, the FDA attempted, for the first time,
160. See infra notes 192-93 and accompanying text.
161. Janssen, supra note 94, at 430.
162. Id.
163. Id. Another problem was that "drugs too dangerous for lay use were increas-
ingly being sold over-the-counter." Id. See infra notes 173, 294 & 295 and ac-
companying text.
164. Janssen, The U.S. Food and Drug Law: How It Came; How It Works, 35 FoOD
DRUG COSM. L.J. 132, 134 (1980).
165. Id.
166. Janssen, supra note 94, at 431.
167. Id.
168. Id.
169. Id.
170. Id.
171. Id.
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to restrict to professional channels those drugs deemed to be un-
safe for use by the lay consumer.1 7 2 In 1939 a letter was sent to
drug manufacturers stating that label warnings such as "[t]o be
used under the direction of a physician only" were not effective in
preventing over-the-counter sales. 7 3 A stronger, more conspicu-
ous warning was urged. 7 4
On April 15, 1941, revised regulations on directions for the use of
drugs were published in the Federal Register.7 5 These regulations
repeated the original wording of the RX Legend. Shortly thereaf-
ter, the FDA finally supplied a list of drugs which the agency con-
sidered too dangerous for self-treatment and therefore required a
prescription.17 6 The FDA had previously refused trade requests to
supply such a list for two reasons: (1) it was the manufacturer's
responsibility for deciding how to label its drugs, and (2) the FDA
was not authorized under the 1938 statute to provide such a list. 7 7
As one commentator noted, "[T] he Agency hedged its list by say-
ing that it was impossible to provide a complete list of drugs which
could be dangerous in self-medication." 7 8
Nine months later, the United States entered World War II.
The war effort would divert the FDA's resources to the important
new assignment of testing drugs for the military.179 The end of
World War II brought the "drug revolution."180 New prescription
drugs, some being of unimagined chemical formations with com-
pletely unknown effects, entered the marketplace at the rate of 300
to 400 a year.181
Although the role of the FDA had originally been to protect the
American public from the "nostrums, folk remedies, and other
medications which were widely advertised and sold without seri-
ous attention to their presentation,"182 the problem of efficacy in
drugs had now, for the first time, shifted heavily to prescription
products. 8 3 Between 1938 and 1960 an average of 375 new drug
172. Id.
173. Id.
174. Id.
175. Id. at 432.
176. Id.
177. Id.
178. Id. at 432-33.
179. Id. at 433.
180. MINTz, supra note 110, at 50.
181. Id.
182. DIxON, supra note 23, at 5-3. Today the FDA controls manufacturing proce-
dures, drug advertising, drug labeling and practically all communications be-
tween the drug manufacturer and the practitioner who prescribed the drug.
Id. at 5-10. The FDA is also charged with evaluating the effectiveness of ap-
proved drugs. Id. See infra notes 202-09 and accompanying text.
183. Mlr, supra note 110, at 50.
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products a year were cleared by the FDA.184 Although many of
these drugs did not contain unique ingredients or chemical entities
the task of reviewing them was far beyond the capacity of the
agency.185 Consequently, the FDA delegated the review of drugs
entering the marketplace between 1938 and 1962 (including those
drugs for which new approval was sought) to the panels of the Na-
tional Academy of Science and the National Research Council.186
During this twenty-four year period, pharmaceutical manufac-
turers filed 13,623 new-drug applications, of which 9,097 were
cleared by the FDA.187
According to one expert, this rapid increase in the introduction
of new drugs (especially as seen in the 1950s) made the FDA in-
creasingly conscious of a very serious problem:
The drug manufacturers were replacing the medical schools as the
principal source of information for physicians in their use of new drugs.
The informative labeling worked out by FDA with applicants in the course
of processing New Drug Applications, was not reaching physicians. This
labeling, in accord with the regulations, was referred to on the drug label
as "available to physicians on request." The pharmaceutical industry,
however, was [instead] promoting the use of these potent new drugs to
physicians by detail men, mailing pieces, medical journal advertising, and
reference publications that frequentlyfailed to disclose their hazards.1 8 8
As a result, the more informative labeling was rarely "requested"
by the physician and there was no assurance that the information
would indeed be provided in response to requests. 8 9 As this dan-
ger was recognized, the FDA required new drugs to include the
informative labeling as part of the prescription drug package.190
But such actions proved to be an inadequate solution to a danger-
ous problem. The flood of new products had created an "informa-
tion lag"'91 and with it the need for new legislation.
E. The 1962 Drug Act Amendments and "Kevadon"
On April 12, 1961, Estes Kefauver, a United States Senator from
Tennessee, introduced legislation which required the manufactur-
ers of prescription drugs to prove that their drugs were both safe
184. Id. at 51.
185. Eaton, supra note 129, at 21; see infra note 215.
186. Eaton, supra note 129, at 21. This action did not occur until after the 1962
amendments were passed. See 21 C.F.R. § 130.38 (1967). See also infra notes
202-06 and accompanying text.
187. MInrz, supra note.110, at 51.
188. Dr. Ralph G. Smith, former director of the FDA's division of new drugs, in a
1968 paper to the American Society of Hospital Pharmacists, reprinted in
Janssen, supra note 94, at 436 (emphasis added).
189. Janssen, supra note 94, at 436.
190. Id.
191. Id. at 437.
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and efficacious before they would be allowed to market them.192
This shift in the burden of proof regarding a drug's attributes from
the FDA to the drug manufacturers193 resulted in a battle in Con-
gress of the intensity like none other since the 1906 Act.
Kefauver's steadfast fight in the Senate against his colleagues
(particularly Senators Hruska and Dirksen, from Nebraska and Il-
linois, respectively) to gain passage of the drug reform amend-
ments is interestingly and enlighteningly portrayed in the book
The Real Voice .194 When the smoke had cleared, the impetus that
pushed the legislation past its many opponents came from a most
unlikely source.
The Wi. S. Merrell Company filed a new drug application on
September 12, 1960.195 The new drug, to be sold in the United
States as "Kevadon," would have carried labeling which stressed
its value in combatting nausea during pregnancy.196 Merrell dis-
tributed 2,528,412 tablets in a variety of colors and sizes to 1,267
doctors nationally on an investigational basis. The doctors, in turn,
gave the tablets to some 20,000 patients in containers that bore
nothing more than directions for use.197 This new drug soon made
worldwide headlines as the results of its terrifying side effects on
the newborn babies of thousands of women throughout Europe be-
came apparent.198 The drug, whose American trade name was
192. Eaton, supra note 129, at 19-20.
193. Id.
194. I. HARRis, THE REAL VOICE (1964). "Ultimately, the job of serving as [drug]
industry spokesman fell to Senator Roman B. Hruska, an archconservative
from Nebraska .... According to one industry representative, Hruska was,
if anything, too devoted to his task." Id. at 69. As the representative ex-
plained, "Instead of concentrating on the drug industry's considerable
achievements and letting the ugly facts pass by as quickly and unobtrusively
as possible, Hruska defended everything the industry had ever done and at-
tacked the least significant criticisms of it at endless length." Id. Kefauver
was especially annoyed by Hruska's behavior, stating, "In all my years in
Congress, I've never encountered such harassment, obstructionism, and vili-
fication." Id.
195. Eaton, supra note 129, at 18 n.72.
196. Id.
197. HARuus, supra note 194, at 209.
198. The drug, developed by the German firm, Chemie Grunethal, was extensively
sold in Western Europe, England, Canada, Brazil, Japan, and other countries
as a sedative. Since it produced a deep sleep without the "hangover" effects
of other sedatives, it achieved great popularity and was "manufactured liter-
ally by the ton." S. REP. No. 1744, 87th Cong., 2nd Sess. reprinted in 1962 U.S.
CODE CONG. & AD. NEWS 2884, 2905-06. When given to expectant mothers in
early pregnancy, their babies in some cases were born with assorted malfor-
mations, particularly a condition called phocomelia, or "seal limbs" because
the hands and feet are attached close to the body like flippers, with little or no
arms or legs. Id. As many as 5,000 malformed babies were born in Europe,
reaching "epidemic proportions" in the fall of 1961. Id.
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Kevadon, was the sedative thalidomide.199 The only reason that
the drug had not been marketed commercially in the United States
was because a FDA medical officer, Dr. Frances 0. Kelsey, had re-
fused to release the drug based on what she believed was inade-
quate evidence.200 One commentator described what followed
next: "The headlines screamed, the public was aroused, the drug
manufacturers ran scared, and the opponents of [Kefauver's]
tough bill jumped for cover."2 01
One of the most important elements of the 1962 Amendments
was the additional authority given to the FDA. The Act required
drug manufacturers to not only keep records, but to report on ex-
periences with each drug on the market as new data became avail-
able.20 2 One of the primary purposes of the new amendments was
to ensure that the FDA had access to current information, so that
the agency could make informed judgments about the marketing
of the drug.2 0 3 The Act empowered the FDA to require drug manu-
facturers to make reports on human experiences with experimen-
tal drugs prior to the submission of a new drug application, as well
as to keep records of all adverse drug reactions. 204 Other new pro-
visions with respect to investigational drugs required informed pa-
tient consent before trials on human subjects. Drug companies
were required to register their establishments with the FDA and
be subject to an inspection at least once every two years.2 05 Very
importantly, companies were required to show, by substantial evi-
199. See supra notes 195-98 and accompanying text.
200. Janssen, supra note 94, at 437.
201. Id. (quoting from Dr. Harry Dowling's book, MEDICINES FOR MEN).
202. See infra note 203.
203. Eaton, supra note 129, at 21. See infra notes 204-06, 209 and accompanying
text. The new regulations require drug manufacturers to make periodic
safety reports. Furthermore, manufacturers must report within 15 days any
information they receive regarding adverse effects if such effects had not
been reported in the new drug application or encountered during subsequent
clinical trials. Eaton, supra note 129, at 23.
204. At the heart of the 1962 law was the requirement that no new prescription
drug could be admitted into interstate commerce until the manufacturer had
filed application with the FDA providing proof that the drug was both safe
and effective. Rheingold, supra note 16, at 960. For a lengthy discussion and
definition of what the term "new drug" means, see DIXON, supra note 23, at 5-
12 & 5-20-23. After the clinical trials are complete, the manufacturer will sub-
mit a new drug application (NDA). The NDA is the required proof that the
drug is safe and effective as represented by the manufacturer. For a discus-
sion of the NDA process, see DIXON, supra note 23, at 5-22 to 26; see infra note
206. The 1962 amendments placed the burden on the proponent of the NDA to
show "by substantial evidence" that the drug would have the effect it
promises. Drug Amendments of 1962, Pub. L. No. 87-781, § 102(b), 76 Stat. 780,
781 (1962) (amending ch. 675, 52 Stat. 1052 (1938)).
205. See DIXON, supra note 23, at 5-5--5-6 for a discussion of the thrust of the 1962
amendments.
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dence from controlled studies, the effectiveness as well as the
safety of new drugs, in order to obtain requisite FDA approval for
marketing. The new regulations implementing the 1962 Amend-
ments closed many of the loopholes which had previously ex-
isted.206 Obviously, preventing violations through premarketing
clearance procedures affords consumers far better protection than
does the alternative of merely prosecuting violations after the inju-
ries have been reported. The trend towards preventive law has
slowly evolved with each successive step in the legislative process.
As had been the case with the 1906 Act, most drug manufactur-
ers did not react kindly to the new restrictions and regulations.
2 0 7
One commentator observed that after passage of the 1962 Amend-
ments, "the drug industry, acting primarily through the Pharma-
ceutical Manufacturers Association (PMA), continued to fight a
legal, political, and regulatory battle against enforcement of the
Act's reporting provisions."208 Claims by certain drug companies
that the H.E.W. Secretary could not require them to file reports
because their drugs were "old drugs"20 9 reached the United States
206. The reporting provisions took immediate effect for NDA's received after Octo-
ber 10, 1962, the effective date of the Act. The regulations require drug manu-
facturers to establish and maintain records as well as prepare reports
necessary to allow the FDA to determine whether the drug should be sus-
pended or approval withdrawn under section 505(e) of the Act. 21 C.F.R.
§ 310.300 (1980). See supra notes 203-05; infra note 209.
207. See supra notes 131-32 and accompanying text.
208. Eaton, supra note 129, at 24. The PMA, as one commentator observes, is a
"heavily financed organization [which] has waged battle against every en-
emy of the industry." DiXoN, supra note 23, at 6-2. The PMA has been "partic-
ularly effective" with legislative groups, physicians' organizations and the
FDA. " Te PMA has... maintained a very close relationship with the FDA,"
with informal meetings between the FDA and the PMA "held on a frequent,
regular basis." Id.
209. Eaton, supra note 129, at 24-25. The requirements for "new drug" applica-
tions (NDA's) underwent major revisions under the 1962 Amendments.
Before the 1962 Amendments, previous legislation had made an NDA auto-
matically effective if the FDA did not take affirmative steps within 60 days by
acting either to accept, deny, postpone, or suspend the application where un-
true statements were made or where new methods were developed which
revealed the drug to be unsafe after the date of the application. Federal Food,
Drug, and Cosmetic Act, ch. 675, § 505(c), 52 Stat. 1040, 1052 (1938). The 1962
Amendments no longer allowed automatic clearance of new drugs merely
due to the FDA's failure to act Furthermore, a drug cannot be marketed un-
til it has received affirmative FDA approval as having met the requirements
for safety and efficacy. The FDA was also given a 180-day period for initial
consideration of the NDA, subject to further extension. The final decision,
based on a formal hearing, could be postponed for another 180 days or more.
Drug Amendments of 1962, Pub. L No. 87-781, § 104(b), 76 Stat 780, 784 (1962)
(amending Federal Food, Drug, and Cosmetic Act, ch. 675, § 505(c), 52 Stat.
1040, 1052 (1938)). The usual NDA today is a massive document comprised of
data collected over a period of years which includes clinical trial information,
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Supreme Court. Unlike the Court's action in United States v. John-
son,210 where consumer drug legislation had been weakened, the
Court affirmed that the power indeed existed to enforce the new
provisions.21 But although in theory the power is there, the FDA
has repeatedly been criticized not only for failing to fully enforce
the provisions of the 1962 Amendments, but for maintaining a
"close working relationship" with the PMA as well as with individ-
ual members of the drug industry.212 Critics of the FDA have
noted that the FDA's position has been that it can work more
closely with individual manufacturers "as a partner rather than a
policeman."2 13 But since 1962, literally thousands of prescription
drug products have been taken out of the U.S. marketplace be-
cause they lacked evidence of effectiveness and/or safety, or be-
cause their labeling required changes to reflect known medical
facts. Product recalls have become a major means of consumer
protection under the law. Although the FDA prefers to promote
compliance by means other than going to court, when a manufac-
turer refuses either on its own initiative to recall its product or
upon the request of the FDA to do so, the court route is taken.
Generally, the recall of products by a manufacturer on its own ini-
tiative is the fastest and most effective way to protect the public. 214
Unfortunately, many manufacturers have not made the requisite
submissions,2 1 5 "claiming that serious reactions such as limb
animal testing results, and of utmost importance, the manufacturer's claims
for the drug's safety and efficacy. Rheingold, supra note 16, at 961. The FDA
usually has very little significant active involvement with the drug while it is
in the preliminary evaluation stage and investigational new drug stage.
DixoN, supra note 23, at 5-26. No independent tests are performed by the
FDA or its agents; reporting requirements on adverse and toxic reactions pro-
vide the FDA with notice of drug dangers. Id. See supra note 204.
210. See supra notes 135-36 and accompanying text.
211. The Supreme Court made it clear that the primary power and responsibility
for evaluating the safety and effectiveness of drugs rests with the FDA. See
Weinberger v. Hynson, Westcott & Dunning Inc., 412 U.S. 609 (1973); Ciba
Corp. v. Weinberger, 412 U.S. 640 (1973); Weinberger v. Bentex Pharmaceuti-
cals, Inc., 412 U.S. 645 (1973); USV Pharmaceutical Corp. v. Weinberger, 412
U.S. 655 (1973).
212. DixON, supra note 23, at 6-2.
213. Id. at 6-3.
214. Janssen, supra note 164, at 139. See infra note 215.
215. See supra notes 203-09. It is just not possible for the FDA to annually inspect
all of the firms falling within its jurisdiction. For example, in the food indus-
try alone, there are over 85,000 establishments under the FDA's "regulatory
veil." Weeda, FDA Seizure and Injunction Actions: Judicial Means of Pro-
tecting the Public Health, 35 FOOD DRUG COSM. U.,. 112, 114 (1980). In fiscal
1978, the FDA conducted 19,016 inspections of food establishments, leading to
187 seizure actions, 21 injunctions, and 27 criminal prosecutions. Overall, in
1978 the FDA conducted 34,493 establishment inspections of food, drug, medi-
cal device, cosmetic and biological firms resulting in 829 recalls, 385 seizures,
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deformities or deaths were not 'unexpected',"216 even though the
companies had neither previously reported this type of reaction to
the FDA in their new drug application nor encountered the reac-
tion during clinical tests.217 As a result of so many questionable
actions in the past, the "motivations" of the drug manufacturer
often continue to be suspect when the issues of consumer protec-
tion and profits conflict.2 1 8
IV. THE MANUFACTURERS' ROLE
Where life and health are at stake no specious argument should prevent
the speedy punishment of those unscrupulous men who are willing, for
the sake of gain to endanger the health of unsuspecting purchasers.2 19
Any discussion about the pharmaceutical manufacturer's role
in the entire complicated process of supplying safe and effective
drugs to the consumer must be prefaced with a few
acknowledgements.
The powerful chemical agents produced by the new technology
of the last few decades often have "personalities" that may not be
fully unveiled until they have been used for years by great num-
bers of people.220 This mandates that testing of these products
should "be extraordinarily cautious, thorough, and imaginative
before marketing begins."22 1 The lesson from the DES tragedy is
clear on this point. Yet, on the other hand, how much testing is
enough? How long should investigatory tests using humans last
50 injunctions, and 35 criminal prosecutions. Id. "It is obvious, therefore,
that consumer protection for those firms which escaped FDA inspection dur-
ing 1978 depended upon voluntary compliance." Id. (emphasis added).
216. Eaton, supra note 129, at 25.
217. Id. See DIXON, supra note 23, at 9-59.
218. See supra notes 108-10 and accompanying text; infra notes 219, 221 & 246-49
and accompanying text.
219. Peter Collier, U.S. Dept. of Agriculture, 1879 noted in Litman, supra note 91,
at 660.
220. Mnrrz, supra note 110, at 161. See supra notes 5 & 90. See also infra notes 221
& 222.
221. Mmz, supra note 110, at 161 (emphasis added). Testing procedures may be
affected by the profit motivation. A drug with numerous potential advantages
and a large potential market may create pressure for rapid completion of
mandated tests and prompt market approval in order to "corner the market."
DIXON, supra note 23, at 6-9. 'This conflict between scientific prudence and
profit motivation may lead the manufacturer to take calculated risks with the
life of the ultimate consumer in order to gain a competitive advantage." Id.
As one court observed: "[T] here are two risks involved in the development of
new drugs: (1) the risk that unforeseen, perhaps catastrophic, injuries will
result because a new drug is used in man too soon; and (2) the risk that need-
less human suffering and death will occur because a beneficial drug is with-
held from mankind too long." Gaston v. Hunter, 121 Ariz. 33, 48-49, 588 P.2d
326, 341-42 (Ct. App. 1978). See infra note 222.
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before a drug is marketed? As one commentator observed, "Just
as it is intolerable to have a drug released too quickly, so would it
be intolerable-although this has not been shown to be a prob-
lem-to hold back a valuable new drug out of fear, or out of unwill-
ingness to take a knowledgeable and intelligently calculated
risk."222 Likewise, drugs are perhaps different from any other
product available, because every drug is a potential poison. Unlike
other products, which are designed to be safe when properly used,
a drug can cause a disaster even when the most painstaking pre-
cautions known to science have been taken.223 In spite of these
dangers, the drug may prove to be beneficial and even life-saving.
Another element which makes drugs unique from other products
is the fact that knowledge about a drug is an inherent part of the
drug as a product. "Without knowledge of a drug, it is valueless.
With knowledge, society accepts the place of drugs as a meaning-
ful part of our world." 224 Thus, the drug manufacturer is actually
selling knowledge as well as a product.
From the manufacturers' perspective, new drugs require very
large investments of capital, energy and time. Investments for de-
velopment and testing as well as adherence to FDA requirements
and procedures are all essential ingredients in the process that will
put a new drug in the consumer's hand. Of course, as with any
product, extensive planning, advertising, and promotion of the new
drug and its desirability and benefits must take place.
222. MIN'rz, supra note 110, at 161-62. "The drug industry is one of both high prof-
its and high returns." Comment, DES and a Proposed Theory of Enterprise
Liability, 46 FORDHAM L REV. 963, 975 (1978). The number of women who
took DES will never be known, but one source estimates that as many as
three million women ingested the drug during their pregnancies. Id. at 965
n.6. Fortunately, the risk of cancer developing in their exposed offspring is
relatively small given the large numbers involved. But this is no consolation
to the perhaps thousands of women who were affected. Estimates range from
a high of one in 250 (12,000) to a low of one in 10,000 (300). Id. at 965 n.7. It is
true that a "drug lag" results when drugs are withheld from the public when
the manufacturer attempts, through testing, to uncover potentially serious
side effects. It is also true that a drug manufacturer will never be sued by
those who suffer because a drug was not released. The painfully slow pro-
gress in consumer drug law protection requires that the time be taken.
223. DIXoN, supra note 23, at 9-2. "In a sense, drugs are different from other prod-
ucts because every drug can be a poison." Id. (emphasis added). See infra
note 224.
224. Id. at 9-3. Likewise, drug labeling is different from the labeling of other prod-
ucts in the marketplace. The information in drug labeling can be just as im-
portant to the physician and the patient (consumer) as the drug itself.
Janssen, supra note 94, at 440. See supra note 223 and accompanying text.
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A. Marketing and Overpromotion
A recent Harvard study2 25 reveals both interesting and perhaps
surprising data about factors which influence physicians' choices
of drugs for their patients. Dr. Jerry Avorn and his colleagues
asked eighty-five randomly chosen Boston-area physicians how
they choose the drugs they prescribe. Most of the doctors stated
that scientific papers were "very important" in their decision-mak-
ing, while drug advertisements, "detail men," and patient prefer-
ence were only "minimally important."226 The Harvard team then
asked the same physicians questions regarding the proper use of
two kinds of widely misused drugs-cerebral vasodilators (drugs
that open up blood vessels and theoretically improve circulation)
and propoxyphene (a pain killer best known under the trade name
Darvon). Dr. Avorn noted that had these doctors been reading the
medical literature they would have known that vasodilators were
no longer considered useful in the treatment of senile mental fail-
ure, and that Darvon was considered to be less effective than com-
mon aspirin in treating moderately severe pain. 2 27 Instead, the
responses of most of the physicians indicated that they had ac-
cepted the claims of the manufacturers.22 8
1. Publicity and Promotion
As in any industry, control of demand for a product is com-
pelled by the need to assure a corporation's growth, stability, or
even its survival.22 9 Be it General Motors or Eli Lilly and Com-
pany, advertising and promotion are the basic tools used in con-
trolling demand. But in the case of the drug marketplace, different
variables must be taken into consideration. Although a consumer
may be quite capable of deciding whether an automobile is good or
bad, he cannot reliably ascertain whether a medicine is really good
or bad. This is especially true about prescription drugs, but it is
also true on a lesser scale about nonprescription over-the-counter
drugs. Thus, with prescription drugs, the physician acts as a
"learned intermediary" 23 0 between the manufacturer and the ulti-
mate user (consumer). Because of this special status, the pre-
scribing doctor usually decides which prescription drug to buy and
in this context, the ultimate user's importance as a consumer is
secondary. The physician then becomes the target of a wide vari-
225. J. Avorn, Scientific Versus Commercial Sources of Influence on the Prescribing
Behavior of Physicians, 73 A.J.M. 4 (1982).
226. Id. at 4-5.
227. Id. at 5-6.
228. Id. at 6-8.
229. See infra notes 230-32 and accompanying text.
230. See infra notes 265 & 288 and accompanying text.
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ety of publicity regarding a new drug.23 1 The manufacturer's chal-
lenge is consequently to develop its new product, to "patent it,
promote it, advertise it, make a big profit, and then repeat the cy-
cle. '23 2 Hopefully, the patented drug will become the product that
physicians believe should be prescribed. Widely used methods to
meet this end include labeling and package inserts,2 33 free samples
and gifts distributed by manufacturers' detail men,23 4 the Physi-
cians' Desk Reference,235 and numerous advertisements via the
mass media.236 The pharmaceutical industry, in a public relations
231. MmTz, supra note 110, at 163. See Rheinstein, A Head Star a Broader Audi-
ence and an Emphasis on Difference: The New Frontiers of Prescription Drug
Promotion, 37 FOOD DRUG COSM. L.J. 330, 332-33 (1982).
232. MnrZ, supra note 110, at 163.
233. The drug package insert is a brochure which contains information about the
drug. It has also been called a "stuffer", "labeling information", and the
"warning sheet." DIXON, supra note 23, at 6-32. The package insert carries a
summary of adverse reaction information, dosage data, and is included with
the drug package or container when shipped to the pharmacist. The purpose
of the insert is to provide current information regarding the product to the
physician. The information on the insert must be revised whenever neces-
sary to warn of new drug dangers. Id. at 6-32-33. The package insert grew out
of a need to give physicians accurate information regarding a drug's effects,
usage, and dosage, apart from that imparted in the advertising and promo-
tional literature of the drug manufacturer. Barnett, Drug Reactions: The Role
of the Package Insert, 1 J. LEGAL MED. 19 (March/April 1973). In 1961 the
FDA promulgated regulations providing for a package insert to be on or
within all prescription drug packages. 21 C.F.I. § 1:106(3) (i) (1961). Known
as the "full disclosure" regulation, it required that labeling on or within the
package containing the drug bear adequate information for use of the drug,
including- indications, effects, dosages, methods, and frequency. The theory
behind the package insert is that the availability of such information should
help to protect the patient in the use of the drug. DIXON, supra note 23, at 6-
33. Unfortunately, this reasoning is flawed. See infra notes 292-96 and accom-
panying text. One problem is that the package insert may well be outdated,
as many drugs can be safely stored for years without significant change.
DIXON, supra note 23, at 6-34.
234. A detail man is a salesman for the drug manufacturer. Generally commis-
sioned based on earnings from an assigned territory, the detail man "is the
most important liason between the pharmaceutical company and the medical
profession." DIXON, supra note 23, at 6-28. Trained as a salesman, he uses
sales techniques and managerial skills to promote the product. The detail
man personally contacts physicians, attempting to educate them and to in-
duce them to use the company's wares. The average visit lasts for eight to ten
minutes, and may involve the use of gimmicks and gifts as part of the ap-
proach in building rapport with the physician. Id. at 6-29. See infra notes 242-
49 and accompanying text.
235. The Physician's Desk Reference (PDR) is a reference book containing infor-
mation given by drug manufacturers on about 90% of the drugs on the mar-
ket. The PDR is commonly referred to by the physician when prescribing
drugs. See infra note 270.
236. As one commentator asserted: 'The cleverest techniques of modern Madison
Avenue merchandising are being focused on the physician as a prime target
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role, has widely publicized to both physicians and lay consumers
alike the vast amounts of money it spends annually on research.
As one source asserted:
One would assume from the tone of the publicity that vast sums of money
are being spent to discover new drugs, to cure heretofore incurable dis-
eases, and that, as a result of this research, we will rapidly approach a
disease-free world. If this is the intended implication, then some criticism
is in order, for the bulk of pharmaceutical research is definitely directed
toward increasing company profits by developing marketable drugs which
will sell in the largest volumes and make the largest profits.
2 3 7
Although such self-praise may warrant passing criticism, the
problems and dangers presented by the zealous and sometimes
unethical over-promotion of drug products have led to serious
harm to the consumer.
2. Publicity and Overpromotion
Drug companies have learned that doctors are influenced by the same ad-
vertising techniques that are used for mass consumer advertising. They
accept new drugs with amazing rapidity ... in part because it would ap-
pear that a physician's own market position is strongly influenced by his
reputation for using the latest drug.2 38
As Dr. Avorn and the aforementioned Harvard study concluded,
"Drug advertisements are simply more visually arresting and con-
ceptually accessible than are papers in... medical literature, and
physicians appear to respond to this difference." 239
The 1960's saw the FDA espouse regulations which required a
fair balance in all forms of drug advertising, with the practitioner
to be properly warned about any dangers or side-effects of a drug
in equal balance to the manufacturer's claims about the drug's
benefits. 240 Before this crackdown, manufacturers had been free
to make outrageous claims about the value of their drugs. Un-
proven claims of effectiveness and superiority over competitors'
brands were the rule rather than the exception.24' Limited only by
their imaginations and ethics, manufacturers had been able to
"puff up" their wares in the hope of inducing physicians into se-
lecting Brand X over Brand Y. If the new regulations of the 1960's
have toned down promotion abuses, they have not lessened their
costs. The drug industry reportedly spent one billion dollars per
who has the potential to markedly increase the drug company's profit."
DIXON, supra note 23, at 6-26. And these techniques are very effective. See
supra notes 225-28 and accompanying text. See also infra notes 238-39 and
accompanying text.
237. DIXON, supra note 23, at 6-5.
238. FORTUNE, (May, 1960) quoted in M=mZ, supra note 110, at 166.
239. 73 A. J.M. 4, 8 (1982). See infra note 296.
240. DIXON, supra note 23, at 6-23.
241. Id.
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year in the early 1970's on advertising promotion (amounting to
about $5,000 per physician), with a major part of this cost going to
pay the industry's 20,000 drug detail men.242 Often regarded as the
physician's principle source of drug information, detail men fre-
quently find themselves living with "an inherent conflict of inter-
est" created by the pharmaceutical manufacturer.243 On the one
hand, the detail man is a salesman with a product to sell with a
variety of reasons to do so. But the detail man also may be in the
best position to warn physicians of any of his product's dangerous
propensities.2 4 4 Unfortunately, negative news about his products
could frighten away customers, turning them to his competition.
Of course, most detail men answer that they are above such temp-
tations and company pressure, but many of the cases on over-
promotion have emphasized the role of the drug detail man.245 In
Toole v. Richardson-Merrell,24 6 the manufacturer had knowledge
of the dangerous effects of its drug, yet concealed this information
from both the FDA and the medical profession.247 In Toole, a Cali-
fornia court held that the drug company's continued promotion of
the drug with knowledge of its dangerous side-effects constituted
"malice" within the California statute allowing punitive dam-
ages. 2 4 8 In many such instances, company pressure and sales sus-
242. Id. at 6-27 & 28. See supra note 234.
243. Id. at 6-30.
244. Id. See infra notes 247-49, 272-73 and accompanying text. See Note, Torts:
Drug Manufacturer Held Negligent for Failure to Use Detail Men to Warn
Physicians of Dangerous Side Effect, 55 Mum. L REV. 148 (1970).
245. See infra notes 247-49, 272-73 and accompanying text. See Note, Products Lia-
bility: Drug Manufacturer Found Liable for "Over-promotion" by Detail
Men-A Diminution in the Standard of Proof, 45 TEMP. L.Q. 134 (1971).
246. 251 Cal. App. 2d 689,60 Cal. Rptr. 398 (Cal. Ct. App. 1967). In Toole, detail men
were instructed to blame drug side effects on other drugs. Id. For a good
discussion of Toole, see DIXON, supra note 23, at 9-73-75.
247. 251 Cal. App. 2d 689, 60 Cal. Rptr. 398 (Cal. Ct. App. 1967).
248. Richardson-Merrell, it should be remembered, is the same manufacturer that
tried to market thalidomide in the United States. See supra notes 195-200 and
accompanying text. Richardson-Merrell is presently marketing Bendectin in
this country. See supra note 1 and accompanying text. The following excerpt
appeared in THF NEw REPUBLIC and was read into the Congressional Record.
It describes instructions given to Merrell Company detail men regarding the
promotion of one drug-
The William S. Merrell Co. (a division of Richardson-Merrell) whose
anti-cholestral drug MER/29 was ultimately taken off the market be-
cause of side-effects that included liver damage, hair loss, hepatitis
and cataracts, promoted MER/29 with elaborate. . . manuals asking
detail men to assure doctors that the drug worked, was safe, and
should be prescribed. Salesmen were told, in sentences puncutated
[sic] with multiple exclamation marks, to memorize a pitch and
know it well enough that it could not be seen through as "canned."
They were instructed to affect excitement ("You owe it to yourself-
to your company--to the millions of people who need MER/29, to be
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ceptibility and not the desire to warn the physician (consumer) of
uncertain dangers have proved to be the true motivating factor be-
hind detail men's actions.A 9
B. , Warnings, Warranties, and Products Liability
Thou shalt warn your fellow man, do not let sin befall him.
25 0
Section 402A of the Restatement of Torts exempts dangerous
products from strict liability if they are properly prepared and
marketed and a "proper warning is given."2 51 Thus, under the rea-
soning of comment k to section 402A, the special treatment estab-
enthusiastic!!!") and told how to deliver the line ("Lean forward-
toward the doctor. Automatically tighten your stomach muscles as
you make your presentation. This forces a change in the inflection of
your voice and paves the way for deeper penetration of the benefits
you are describing.") Finally, the detail men were told how to shift
any doctor's suspicions about a Merrell drug to medicine made by
other firms ("Even if you know your drug can cause the side-effect
mentioned, chances are equally good the same effect is being caused
by the second drug. You let your drug take the blame when you
counter with a defensive answer. Know how to answer side-effects
honestly, yes, but get the facts first. Doctor, what other drugs is the
patient taking? Been doing it for years? Why didn't you tell us
then?"). This line supposedly got the clottish physician to attribute
undesirable side-effects to Upjohn or Lilly. The tactic was rational-
ized because, rhetoric aside, the cause was good: 'There is no longer
any valid question as to its (MER/29) safety or lack of significant
side effects."
Sanford, Drug Peddlers, THE NEW REPUBLIC 16-17 (Sept. 21, 1968), quoted in
114 CONG. REC. 12,710-711 (daily ed. Oct. 12, 1968).
249. See supra notes 244-48 and accompanying text. See also infra notes 272-73
and accompanying text. It should be observed that the physician, ap-
proached by detail men giving large volumes of drug samples, gimmicks, and
assorted gifts, is also placed in a position of vulnerability. DIXON, supra note
23, at 6-51. Sales presentations are carefully framed to describe the finest at-
tributes of the drug, and gifts are calculated to reinforce the physician's mem-
ory of the product's virtues. Id. at 6-51, 52. Salesmen's discussions are not
regulated by the FDA and those gifts to doctors have been known to include
such trifles as color television sets, freezers, and expense-paid trips. Id. at 6-
52. See Kennedy Committee Hearings, Washington Post, March 9, 1974. See
also The Ubiquitous Detail Man, 1 HOFsTRA L Rsv. 183 (1973).
250. Leviticus 19:17.
251. RESTATEMENT (SECOND) OF TORTS § 402A (1965). Although a prescription
drug manufacturer is able to avoid strict liability by giving a warning that
describes a drug's dangerous side effects, the manufacturer's burden in issu-
ing a proper warning is 'more onerous" than that of most other manufactur-
ers. Note, Torts-Product Liability-Duty to Warn-A Drug Manufacturer's
Detail Men Must Warn Physicians on Whom They Regularly Call of the Dan-
gers Involved in the Use of the Manufacturer's Drugs, 45 NOTRE DAME LAw.
135, 137 (1969). While the manufacturer of other products generally is not
required to warn of dangers that would affect a small group of "idiosyncratic
or allergic" users, this rule has a stricter application for drug manufacturers.
Id. See infra note 256 and accompanying text.
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lished for drug manufacturers recognizes that balancing the
desirability of marketing useful drugs to combat disease with the
risk of severe side effects to a handful of susceptible users will of-
fer drug companies some limited protection and induce them to
provide society with valuable drugs.252 But the important question
remains as to what constitutes a "proper warning." The courts
have addressed this question on numerous occasions. The result
has been a good deal of disagreement and a dearth of clear-cut an-
swers. The large majority of drug-related litigation in the 1960's
was based upon the manufacturer's obligation to warn of known
drug dangers.25 3 As a result, manufacturers soon developed the
defense that early reports of drug reactions were just too rare to
require a full warning of danger. Consequently, "the duty to dis-
cover" resulted from the manufacturers' successful use of this de-
fense.25 4 As one source asserts, "In the world of drug testing and
marketing, the question is not whether a drug does cause a partic-
ular injury, but whether it may."255 This lower threshold is per-
haps one advantage for the consumer seeking compensation for
drug-related harm. In a 1968 decision, the United States Court of
Appeals for the Ninth Circuit held that the lower court had erred
252. Comment k of the Restatement of Torts defines unavoidably unsafe products
as those "which, in the present state of human knowledge, are quite incapa-
ble of being safe for their intended and ordinary use .... Such a product,
properly prepared, and accompanied by proper directions and warning, is not
defective, nor is it unreasonably dangerous." RESTATEMENT (SEcoND) OF
TORTS § 402A comment k (1965). In the case of drug manufacturers:
The seller of such products, again with the qualification that they are
properly prepared and marketed, and proper warning is given,. . . is
not to be held to strict liability for unfortunate consequences attend-
ing their use, merely because he has undertaken to supply the public
with an apparently useful and desirable product, attended with a
known but apparently reasonable risk.
Id. Thus, strict liability does not attach to the drug manufacturer unless the
drug is "defective" or "unreasonably dangerous." The drug is "unreasonably
dangerous" only if manufactured improperly or if the manufacturer failed to
properly warn the physician of any dangers inherent in the use of the drug.
Note, Products Liability--Drug Manufacturer's Liability for Overpromotion
of the Use of a Prescription Drug, 10 GA. ST. B.J. 450, 455 (1974).
253. DIXON, supra note 23 at 9-39.
254. Id. The duty to test requires a manufacturer to take reasonable steps to dis-
cover the dangerous properties of its products. Id. at 9-44. A large number of
cases have discussed the manufacturers' obligation to test or discover as part
of basic principles of liability. Id. "Usually the cases have discussed both the
obligation to discover and the obligation to test because they have both been
part of the same factual situation which placed the manufacturer on notice of
facts which require further action." Id. The MER/29 (triparanol) cases in-
volved some of the "most aggravated breaches of this duty," as typified by
Toole v. Richardson-Merrell Inc. Id. See supra notes 24648 and accompany-
ing text.
255. DIXON, supra note 23, at 9-39.
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in failing to instruct the jury that strict liability attached to the sale
of a drug to the plaintiff (and consequently there was a duty to
warn the plaintiff) even though there had been only a one-in-a-mil-
lion chance that the drug would cause the plaintiff's
poliomyelitis.2 5 6
Today, when a manufacturer has notice of a drug injury, its ad-
vertising literature must warn of the danger,2 57 and the warning
must be "proper." As a matter of practice, drug package inserts 25 8
warn of potential drug injuries which are very rare. For instance,
one expert states that a serious reaction with a suspected inci-
dence rate of less than one in ten thousand is now regularly in-
cluded in the warning information about the drug on the package
insert.2 5 9
In the drug litigation arena, the classic "failure to warn" fact
situation lies at the heart of the manufacturer's liability, perhaps
overshadowing many of the more traditional product liability theo-
ries such as negligence,260 warranty,2 61 nuisance,262 and fraud and
256. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1968). For a discus-
sion of the Davis case, see Note, Products Liability-Drug Manufacturers-
An Absolute Duty to Warn Exists Notwithstanding Miniscule Statistical
Probability of Harm, 18 DE PAUL L. REV. 829 (1969). Many idiosyncratic reac-
tions are known to frequently occur. Because of this, the test for liability
should not be whether the drug user is an unusually sensitive person, but
rather whether the drug reaction can be anticipated or predicted. "IT]his is
particularly important where the adverse drug reaction, even though possibly
rare, may have catastrophic results." DIXoN, supra note 23, at 9-25. See
DIXON, supra note 23, at 9-25 to 34. In a 1966 case, the Eighth Circuit Court of
Appeals held that the manufacturer had a duty to reasonably warn plaintiff's
doctor, notwithstanding plaintiff's hypersensitivity. Sterling Drug, Inc. v.
Cornish, 370 F.2d 82, 85 (8th Cir. 1966).
257. DIXON at 6-19. The quality of the warning and the balance of warning versus
promotion now receive "tremendous scrutiny." Id. at 9-7. See supra notes
233-36; infra note 266 and accompanying text.
258. See supra note 233.
259. DIXON, supra note 23, at 6-19.
260. A negligence theory requires the plaintiff to establish the existence of a duty
and a corresponding breach of that duty which in turn is the proximate cause
of the harm done. Originally, a negligence action was the primary method for
recovering damages from manufacturers for physical injuries caused by their
products. The success or failure of the negligence action turned on the plain-
tiff's ability to isolate the defendant's specific negligent act and prove by a
preponderance of the evidence that negligence was the proximate cause of
the plaintiffs injury. The theory of defective manufacture in a negligence ac-
tion is rarely used in drug liability cases for a number of reasons. The prod-
uct is "inherently consumed during its use" and "is rarely available for
analysis to determine whether it was safely manufactured, made in the right
quantities, or was even the right drug." DIXON, supra note 23, at 9-34. An-
other problem relates to the recognition of an injury. "If a steering column in
a car fails, the effects are immediate and apparent. This does not occur with
drugs. A wide range of complicating problems may develop in a patient, and
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misrepresentation. 263
It is the very nature of the drug product itself that has influ-
enced the trend away from some of these areas of products liabil-
ity law, although in reality, they are all interrelated.264 Public
policy demands that certain drugs be used notwithstanding the
a drug-related problem may be one of a multitude of possible causes." Id. at
9-34 to 35. Recently, the Oregon Supreme Court ruled that a physician who
prescribes a drug based on the manufacturer's representations, which negli-
gently failed to warn of the drug's attendant risks, may recover from the drug
company for the damage to his reputation. Oksenholt v. Lederle Labs., 294
Or. 213, 656 P.2d 293 (1982). The court noted that FDA regulations impose a
duty to inform doctors of possible effects of prescription medicines. Breach
of that duty constitutes negligence per se. Id.
261. A warranty theory requires the plaintiff to prove the existence of an express
or implied warranty and its subsequent breach. Courts, frequently faced
with a severely injured plaintiff "strained to ease this burden" and recog-
nized a cause of action for personal injury under a contract-like theory of
breach of implied warranty. Adverse Drug Reactions,supra note 17 at 738, 39.
One commentator has asserted that drug litigation has been less dependent
upon warranty and strict liability theories of recovery than on other areas of
products liability law. DIXON, supra note 23 at 9-82.1. For an indepth look at
the warranty theories (implied and express) of recovery, see DIXON, supra
note 23 at 9-82.1 to 106.
262. Nuisance theory holds that the manufacturer's or supplier's responsibility
runs not only to the ultimate consumer, but also to anyone who could reason-
ably have been expected to be exposed to the products use. See Note, Prod-
ucts Liability-Drug Manufacturers--An Absolute Duty to Warn Exists
Notwithstanding Miniscule Statistical Probability of Harm, 18 DE PAuL L,
REV. 829, 831 (1969).
263. Fraud or misrepresentation theories require the plaintiff to prove the false
statements were made as to a specific product, that the defendant had knowl-
edge of the product's dangerous properties, that the plaintiff relied on the
defendant's representations, and, that a reasonable use of the product as rep-
resented resulted in the harm done to the plaintiff. See DIXON, supra note 23,
at 9-59-69.
264. As the Michigan Supreme Court stated:
Determination of whether a product defect exists because of an inad-
equate warning requires the use of an identical standard. Conse-
quently, when liability turns on the adequacy of a warning, the issue
is one of reasonable care, regardless of whether the theory pleaded is
negligence, implied warranty, or strict liability in tort.
Smith v. E.R. Squibb and Sons, Inc. 405 Mich. 79, 83, 273 N.W.2d 476,480 (1979).
Actions alleging a breach of the manufacturer's duty to warn have thus been
successfully brought under the various theories. See, e.g., Schenebeck v.
Sterling Drug, Inc., 423 F.2d 919 (8th Cir. 1970) (negligence); Grinnell v.
Charles Pfizer & Co, 274 Cal. App. 2d 424, 79 Cal. Rptr. 369 (Ct. App. 1969)
(breach of warranty); Davis v. Wyeth Labs., Inc., 399 F.2d 121 (9th Cir. 1968)
(strict liability). The Ninth Circuit Court of Appeals held that it was not er-
ror to present to the jury the issue of a manufacturer's duty to warn under
warranty theory instead of strict liability because "It]he difference is largely
one of terminology." Davis v. Wyeth Labs., Inc., 399 F.2d 121 at 126 (9th Cir.
1968). For a good discussion of this area, see Adverse Drug Reactions, supra
note 17.
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risks and dangers involved, since the many benefits of their use far
outweigh the disadvantages. In addition, today there is a federal
regulatory agency which must decide in this "societal risk versus
benefit" context, whether the product should be marketed. But, if
there is a chance of injury, it is the informed consumer and not the
drug manufacturer who should have the opportunity of weighing
the risks involved in taking the drug. •
The manufacturer's duty to warn extends to that class of people
for which the drug was intended. This fact helps to define what is a
" proper warning". The FDA is given responsibility for two types of
drugs: prescription drugs and over-the-counter medications. In
practice, both categories must be shown to be generally safe for
the use intended, or their limitations must be so defined.
1. Prescription Drugs
A prescription drug is one that requires a licensed practitioner
to prescribe it.265 Many of the same methods used by manufactur-
ers to promote a product are also used to provide warnings of the
product's dangers or side-effects. As such, the issue becomes
whether a particular statement is a warning or advertisement.
Where the manufacturer warns but his warning is lost in volumi-
nous verbiage, or where the dangers are minimized within adver-
tisements designed to sell the drug,266 the duty to warn is not
satisfied. In fact, an inadequate or inaccurate warning may have
the same result as no warning at all in many instances.
In the case of prescription drugs, the adequacy of the warning is
a question of fact for the jury. The scope of material which the jury
may consider in this determination sometimes extends beyond the
warning material on the package insert. For example, in Love v.
Wolf,267 the plaintiffs decedent died as the result of taking the
drug Chloromycetin. An action followed against the drug manu-
facturer for negligent failure to properly warn. The California
265. The terms "licensed practitioner" and "prescription drug" contain special
meaning under federal law. Although not well defined, the category of li-
censed practitioner includes medical doctors, osteopathic physicians, podia-
trists, optometrists, chiropractors, naturopaths, nurse practitioners,
midwives, and physicians' assistants. Many of these practitioners are given
varying authority to prescribe drugs under various state licensing provisions.
Id. at 5-11. A prescription drug under 21 U.S.C. § 353(b) (1) is defined as a
"drug intended for use by man which-(A) is a habit-forming drug to which
§ 502(d) applies; or (B) because of its toxicity or potentiality for harmful ef-
fect ... is not safe for use except under the supervision of a practitioner li-
censed by law to administer such drug... ." See infra notes 288-89.
266. See supra notes 255-60 and accompanying text. See also infra notes 268-76
and accompanying text.
267. 226 Cal. App. 2d 378, 38 Cal. Rptr. 183 (Ct. App. 1964).
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court observed that the labels on the drug package insert were
probably adequate to warn the physician of the side effect in ques-
tion.268 The court then took notice that there were other more ef-
fective materials and methods that the drug manufacturer used to
persuade physicians to prescribe the drug, stating, "[W] e must ac-
cept the evidence leading to justifiable inferences that Parke-Davis
[the manufacturer] . . . had watered down its regulations-re-
quired warnings and had caused its detail men to promote wider
use of the drug by physicians than proper medical practice justi-
fied."269 The court concluded that it was a proper question for the
jury whether an otherwise adequate warning had been "watered
down" by the manufacturer's promotional efforts, including detail
men, reminder advertising, and the Physician's Desk Reference.27o
A federal district court in Yarrow v. Sterling Drug, Inc. ,271 de-
termined that the drug manufacturer must effectively warn doc-
tors of even rare or remote side-effects inherent in the use of the
drug.272 The court then found that even though the manufacturer
sent physicians a letter with the appropriate warning of the side-
effects, this warning was not the most effective means of making
physicians aware of the danger. Furthermore, the court found that
to warn effectively, the manufacturer should use the same medium
that it finds most effective in promotion of the drug, which in this
case was the company's detail men.273
268. Id. at 402, 38 Cal. Rptr. at 195-96.
269. Id. at 404, 38 Cal. Rptr. at 197.
270. Id. Manufacturers are now making a "conscientious and sophisticated" effort
to better assure that communications regarding drugs are seen and read by
physicians. DIXON, supra note 23, at 6-51. These actions come both in re-
sponse to losses in court and perhaps because of the desire to better inform
the physician about the drugs in question. The "Dear Doctor" letters were
seen as a means to rapidly warn doctors of drug dangers and were sent di-
rectly to practitioners. DIXON, supra note 23, at 6-25. Subsequently, it has
became apparent that physicians "bombarded" with the vast mass of materi-
als and advertisements that they are, often did not read the warnings con-
tained in the "Dear Doctor" letters. Id. Today, mailgrams frequently are
used because of their efficiency and eye-catching appeal, with other letters
advising recall of drugs or containing warnings providing prepaid return en-
velopes. Id. at 6-51. "Obviously, this permits the company to ascertain which
physician received the information and which did not" permitting follow-up
notification of those physicians who do not respond. Id. It should be
remembered that the Physician's Desk Reference, although heavily relied on
by physicians as a reference tool for prescribing drugs, is primarily a com-
mercial compilation of drug advertisements, published by a pharmaceutical
manufacturing interest (published by Medical Economics, Inc., a subsidiary
of Litton Publications, a division of Litton Industries).
271. 263 F. Supp. 159 (D.S.D. 1967), af'd, 408 F.2d 978 (8th Cir. 1969).
272. Id.
273. Since the detail man's face-to-face contact with doctors is so extremely im-
portant, the Yarrow court concluded:
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The failure to warn may not have actually caused the physi-
cians to prescribe the drug if the physician learned of the inherent
dangers in the drug's use from other independent sources and pre-
scribed the medication anyway. This causation requirement has
been raised as an effective defense by the drug manufacturer; if
there is no causation, then there is no liability.274 In Incollingo v.
Ewing,2 75 the court found that by overpromoting, the defendant
manufacturer had breached its duty to warn the medical profes-
sion but found that the question of causation was proper to submit
to the jury, holding causation a requisite to finding the manufac-
turer liable for the breach of its duty to warn properly.2 76 The con-
sumer is most often presented with formidable barriers against
recovery, not the least of which is the heavy burden of proving cau-
sation of this type. It should be remembered, though, that this dif-
ficult task involves but one kind of causation. As has already been
discussed, proving the causal link between the drug and the injury
itself is still another problem. This is especially true in the case of
the child born with a serious birth defect. In such a case, the
problems of proving causation are amplified by numerous other
variables and influences (both environmental and genetic) present
The most effective method employed by the drug company in the
promotion of new drugs is shown to be the use of detail men; thus,
the Court feels that this would also present the most effective
method of warning the doctor about recent developments in drugs
already employed by the doctor, at no great additional expense. The
detail men visit the doctors at frequent intervals and could make an
effective oral warning, accompanied by literature on the develop-
ment, that would affirmatively notify the doctor of side effects such
as shown in the facts in this case.
Id. at 163.
274. Issues of causation are constantly litigated. See, e.g., DeLuryea v. Winthrop
Labs., 697 F.2d 222 (8th Cir. 1983). For a good discussion of the causation
problem see Gordon, The Unborn Plaintiff, 63 MIc. L REv. 579 (1965). In the
field of medicine, causal connections are no less difficult to establish. See
Oakley, Causal Inference in Teratology, DRUG AND CHEMIcAL RisKs TO THE
FETUS AND NEWBORN 33 (1980). See also DIXON, supra note 23 at 4A-57 to 63.
Recently, several courts, including the California Supreme Court, have taken
a "new" look at the "old" causation problem. Sindell v. Abbott Labs., 26 Cal.
3d 588, 607 P.2d 924, 163 Cal. Rptr. 132 (1980), cert. denied, 101 S. Ct. 285 (1980).
In Sindell, the court dispensed entirely with the specific causation require-
ment by fashioning a theory of causation based solely on market share. See,
Market Share Liability: An Answer to the DES Causation Problem, 94 HARv.
L. REv. 668 (1981).
275. 444 Pa. 263, 282 A-2d 206 (1971).
276. In Incollingo, the Supreme Court of Pennsylvania affirmed a lower court's
judgment against a drug manufacturer on the grounds that sufficient evi-
dence was presented to warrant going to the jury regarding the issue of
whether the manufacturer's detail men caused a doctor to prescribe a dan-
gerous drug indiscriminately. Id.
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during pregnancy.277
Defendant-manufacturers have also argued that by complying
with FDA regulations on labeling and testing, they, as a matter of
law, have fulfilled their duty to warn. The court in Stevens v.
Parke-Davis and Company278 summarily rejected this argument
and held that such warnings are merely "minimal" in nature and
do not necessarily satisfy the duty to warn.279 In approving a
$500,000 recovery in favor of a brain-damaged infant, the court in
Stromsodt v. Parke-Davis and Company280 observed: "Although
all of the Government regulations and requirements had been sat-
isfactorily met in the production and marketing of Quadrigen, the
standards promulgated were minimal. The defendant still owes a
duty to warn of dangers of which it knew or should have known in
the exercise of reasonable care."281 In a more recent decision, the
court in Michael v. Warner/Chilcott,282 held that the manufac-
turer's warning, which had been adopted verbatim from a regula-
tion under the federal Food, Drug and Cosmetic Act, did not
constitute an adequate warning as a matter of law.283 In another
case, the Texas Supreme Court affirmed a lower court's finding
that the manufacturer's warning was not adequate as a matter of
law simply because it complied with FDA requirements, since
such requirements set only minimum standards.284 In short, mere
compliance with the FDA's warning requirements and regulations
will not be considered a complete defense.
277. See supra notes 64-77, 85 & 87-92 and accompanying text.
278. 9 Cal. 3d 51, 507 P.2d 653, 107 Cal. Rptr. 45 (1973).
279. The court in Stevens observed that even if the drug manufacturer placed a
proper warning on package inserts as required by the FDA, the manufacturer
could erode or even nullify the warning's effect by utilizing various promo-
tional devices including the company's detail men. 9 Cal. 3d at 66, 507 P.2d at
662, 107 Cal. Rptr. at 54. The court concluded that: "The warnings [on pack-
age inserts] given in this case were not so clearly effective as to defeat, as a
matter of law, the inference that they were nullified by overpromotion." 9 Cal.
3d at 67, 507 P.2d at 662, 107 Cal. Rptr. at 54.
280. 257 F. Supp. 991 (D.N.D. 1966), affid, 411 F.2d 1390 (8th Cir. 1969).
281. Id. at 997. In affirming the trial court's decision, the court of appeals reviewed
the Parke-Davis printed warning which stated under the headnote "Reac-
tions" that: "When given in accordance with suggested methods, local and
systemic reaction following the administration of Quadrigen are usually mild.
The incidence is usually no greater than is normally experienced with triva-
lent vaccine." Parke-Davis and Co. v. Stromsodt, 411 F.2d 1390, 1400 (8th Cir.
1969). The court stated, "This is simply not borne out of the evidence in this
case .... " Id.
282. 91 N.M. 651, 579 P.2d 183 (1978).
283. Id.
284. Bristol-Myers Co. v. Gonzales, 548 S.W.2d 416 (Tex. Civ. App. 1976), affid, 561
S.W.2d 801 (Tex. 1978).
[Vol. 62:526
DRUGS DURING PREGNANCY
2. Over-the-Counter Drugs
In 1972, ten years after the statutory mandate to the FDA, a
study was started to evaluate over-the-counter drugs to ensure
that they were effective as required under the statute.285 Unlike
prescription drugs, over-the-counter drugs are sold directly to the
consumer. Thus, the packaging must contain information which
includes adequate labeling instructions and directions for use as
well as information concerning side-effects and other precaution-
ary warnings.286 In a 1979 case, a New Jersey court noted that the
duty of the manufacturer to warn consumers of the specific risks of
over-the-counter drug use derives from the basic marketing princi-
ple within the industry that nonprescription drugs are purchased
by consumers for the purpose of self-medication, typically without
any intended or actual intervention by a physician.
2 87
This logical rationale compares with the concept that the
"learned intermediary" acts for the consumer in making a decision
about prescription drugs, with the physician in a better position
than the ultimate layman consumer to make the best initial drug
choice.288 As a result, regulations protect the manufacturer from a
similar over-the-counter drug information requirement, so long as
when it goes to the pharmacy, the prescribing and precautionary
285. DIXoN, supra note 23, at 5-7; see infra note 284. See also, Henteleff, OTC--a
Privileged Class?, 36 FooD DRUG COSM. L.J. 332, 338, 339 (1981).
286. Id. at 5-11 & 12. Under the 1962 amendments, drugs must be proven to be
effective. The FDA is charged with implementing these provisions. In 1966,
the Fair Package & Labeling Act was enacted to require that products be hon-
estly and informatively labeled. Likewise, the FDA was expected to enforce
the provisions affecting drugs. Id. at 5-6.
287. Torsiello v. Whitehall Labs., 165 N.J. Super. 311, 398 A.2d 132 (N.J. Super. Ct.
App. Div., 1979).
288. The rationale of the "learned intermediary" rule is well expressed in Reyes v.
Wyeth Labs., 498 F.2d 1264 (5th Cir.), cert. denied, 419 U.S. 1096 (1974), where
the court observed.
This special standard for prescription drugs is an understandable
exception to the Restatement's general rule that one who markets
goods must warn foreseeable ultimate users of dangers inherent in
his products. See Restatement (Second) of Torts, Section 388 (1965).
Prescription drugs are likely to be complex medicines, esoteric in
formula and varied in effect. As a medical expert, the prescribing
physician can take into account the propensities of the drug, as well
as the susceptibilities of his patient. His is the task of weighing the
benefits of any medication against its potential dangers. The choice
he makes is an informed one, an individualized medical judgment
bottomed on a knowledge of both patient and palliative. Pharmaceu-
tical companies then, who must warn ultimate purchasers of dangers
inherent in patent drugs sold over the counter, in selling prescription
drugs are required to warn only the prescribing physician, who acts
as a "learned intermediary" between manufacturer and consumer.
Id. at 1276 (emphasis added).
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information is included on the packaging with a package brochure.
The regulations permit the removal of these package inserts before
they are given to the customer. Thus, although the regulations do
not prohibit the manufacturer from providing direct information
about the prescription drug to the consumer, they do allow the
withholding of consumer information.289 One commentator as-
serts that the initial choice of a drug is a different decision than the
decision to continue in the face of potentially serious side effects
or adverse reactions. 290 "The patient package insert should have a
role in avoiding drug injuries. The patient is the only individual to
become initially aware of the early signs which may herald a seri-
ous drug catastrophe. 2 91
One reason for the suggestion that the "prescription consumer"
be afforded the same consideration as his "over-the-counter coun-
terpart" stems from the fact that the theory behind the prescrip-
tion package insert is flawed. This theory suggests that by
including it with the package, the package insert is therefore avail-
able to the physician to read, study, and ultimately use to protect
the patient from the hazards listed. Unfortunately, the regulations
do not require the package insert to leave the backroom of the
pharmacy and to travel to the doctor's office or ward where the pre-
scriptions are subsequently written. As the same commentator
observed, "The pharmacist's time is, therefore, spent in removing
the outer package and the package insert from the box ... so that
his own gummed label identifying the pharmacy, the doctor, the
patient,... etc., can be placed on the container. '292 Thus, there is
no guarantee that the physician will ever read the drug's complete
labeling or be able to keep up with revisions as they are made.
One critic of the FDA approved labeling practice observed that
patients are "jeopardized" by its "frequent ineffectiveness. ' 293
This is because a central assumption about FDA approval of a drug
is that hazards can be minimized with instructions and warnings
in the labeling.294 'This assumption in turn rests, obviously, on the
supposition that physicians will read and follow the directions pro-
vided.295 But experience suggests that faith in the protections af-
forded by label information is often misplaced."2 96
289. See supra note 289.
290. DJXON, supra note 23, at 9-13.
291. Id.
292. Id. at 6-33.
293. Merrill, supra note 15, at 23.
294. Id.
295. Id. at 23-24.
296. Id. at 24. Dr. James Goddard, as FDA Commissioner, described to a Congres-
sional subcommittee the already discussed facts of life:
[T]he prescribing physician.., is, frankly, under siege in my opin-
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V. THE NEW LABELING AMENDMENT: 21 C.F.R. PARTS
201.63 AND 330.2
Warning: As with any drug, if you are pregnant or nursing a baby, seek
the advice of a health professional before using this product 297
The new FDA labeling requirements represent one of the latest
attempts at providing better protection for the American con-
sumer. As has already been examined in this article, the realiza-
tion of effective Government intervention between the drug
manufacturer and the ultimate drug consumer has been painfully
slow. Before discussing the warning regulations, it is appropriate
to briefly reflect upon just how far government intervention has
evolved.
On September 7, 1982, the proposed rules were published. In
issuing the proposed rules, the FDA observed that it "believes that
it is in the interest of the public health to require OTC drugs to
bear a warning against use by pregnant or nursing women in the
absence of professional advice."298 From a consumer's perspective,
the information accompanying the proposed warning provided sig-
nificant language: "Although only a small number of drugs have
been conclusively shown to have adverse effects on the developing
human fetus or newborn, information of this type is inadequate to
establish safety for most drugs."299 This significance stems not
from its scientific content, but from the fact that FDA sources have
admitted that as many as 300,000 products sold over-the-counter
may well be affected by the new regulations!300
This willingness to recognize the need to better protect the un-
born and newly born from devastating birth defects (even when
extremely remote) is nothing short of a giant step forward in drug-
related consumer protection. But should the consumer, placated
ion. He is under siege from magazines, from direct mail, from mov-
ies, from unsolicited and frequently unwanted samples, from
symposia sponsored by drug companies, from printed reports of
these captive symposia, and from the manufacturers' own detail men
who visit the doctor's office one after another, day after day .... It
is a fact of life in this industry and that sheer volume of promotion
and advertising is what sells a drug.
Id. at 25 (quoting from Drug Safety Hearings, pt. 5, at 1995-96. See supra
notes 225-28, 231-34 & 238-39 and accompanying text.
297. The new FDA mandated warning for pregnant and nursing women that is to
appear on thousands of over-the-counter drugs. Amendments to General
Drug Labeling Regulations, 47 Fed. Reg. 54,750, 54,757 (1982) (to be codified at
21 C.F.R. § 201.63).
298. 47 Fed. Reg. 39,470 (1982).
299. Id. (emphasis added).
300. FDA spokesman Ed Nida stated that as many as 300,000 products may be af-
fected by the new warning. Drugs to Carry Warning Labels for Pregnant,
Nursing Women, Omaha World Herald, Dec. 3, 1982, at 4, col 3.
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by this advance, sit back and revel in this progress? Clearly, the
answer is "no."
A. The New Warning: What It Is
In 1972, American jurisdictions unanimously recognized that
one who intentionally or negligently injures an unborn fetus may
be liable for damages.30 1 This unanimity finalized the reversal
from the long-followed decision in Dietrich v. Northampton,30 2
which had denied a cause of action for injuries to the unborn.30 3 It
has been nearly one hundred years since Dietrich was decided.
Obviously, medical science and the law have both experienced ex-
pansive growth and change in the interim. On December 3, 1982,
the rules and regulations for the new labeling requirement were
published.304 On that date they also became effective, although
the manufacturers of affected drug products will have until Decem-
301. Robertson, Toward Rational Boundaries of Tort Liability for Injury to the Un-
born. Prenatal Injuries, Preconception Injuries and Wrongful Life, 1978 DUKE
LJ. 1401, 1402 (1978).
302. 138 Mass. 14 (1884).
303. Id. In Dietrich, the Massachusetts Supreme Court refused to extend criminal
and property law precedents to include a cause of action in tort. Early com-
mon law had recognized that the life of an unborn child was entitled to the
legal protection of the criminal law from the time it stirred in its mother's
womb, and acknowledged that an infant in ventre sa mere, or in the mother's
womb, is supposed in law to be born for many purposes. For a good discus-
sion of Dietrich and the history of tort actions in the area of prenatal injuries,
see, Robertson, supra note 302, at 1404-39. Indeed, the recognition and con-
cept of the fetus as both a patient and a plaintiff indicates how far both pro-
fessions have advanced since Dietrich. "As our society has become more
concerned about adverse environmental agents, the package labeling of
drugs has changed." Oakley, supra note 275 at 37. For example, the Physi-
cian's Desk Reference used to say that a drug was not known to be harmful
where there was little human data. Now, with virtually the same information
on a drug, the PDR will say that the drug is not known to be safe. Id. And
this new interest and awareness is not confined to the medical profession or
the drug manufacturing interests. A recent Life cover story explored the fas-
cinating world of fetal surgery, including corrective surgery ex utero of a 21-
week human fetus. Hollister, The Unborn Patient, LIFE 38 (April 1983). The
article noted that the goal of such surgery itself is to "repair rather than de-
stroy unborn lives" and asked the question, "Does this mean that a 24-week
fetus, considered a bona fide patient by the doctors treating it for
hydrocephalus, is thereby granted the status of 'personhood'?" Id. at 44.
Likewise, the tough questions of who may pursue a cause of action, as in the
case of "wrongful life," are being addressed in the courts in cases such as
Turpin v. Sortini, 31 Cal. 3d 220, 643 P.2d 954, 182 Cal. Rptr. 337 (1982). For an
interesting discussion of Turpin and the "wrongful life" issue, see Note,
Wrongful Life: New Cause of Action Recognized Based Upon Medical Mal-
practice Theory, 62 NEB. L, REv. 175 (1983).
304. Amendments to General Drug Labeling Regulations, 47 Fed. Reg. 54,750
(1982) (to be codified at 21 C.F.R. §§ 5.31(d), 201.63, 330.2).
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ber 5, 1983, to comply.3 05 The final rules and accompanying infor-
mation reiterate the FDA's stance that existing evidence
establishing the "potential for some OTC drugs to have harmful
effects on the fetus or nursing infant warrants warning pregnant
and nursing women." 306
Stated in "twenty-five words or less," 307 the warning applies
only to over-the-counter drug products intended for "systemic ab-
sorption."308 Drugs that are not intended for systemic absorption
need not bear the warning.309 The regulations also provide for ex-
emptions from the pregnancy-nursing general warning require-
ments, where appropriate, upon petition,310 as well as for
exemptions from the warning requirement for those drugs in-
tended to benefit the fetus or nursing infant during the period of
pregnancy or nursing.311
The FDA noted that it selected the word "warning" as a signal
word because it was more likely to attract the attention of consum-
ers than the word "caution".312 The general warning was intended
to cover those drugs for which the available evidence revealed
neither that the product was unsafe nor that the product was safe
for use by these women.31 3 The FDA further observed that "appro-
priate" general warnings "are an important means of educating the
public about drug use."31 4
305. 47 Fed. Reg. 54,750 (1982).
306. Id.
307. See supra note 298 and accompanying text.
308. The FDA states that it does not intend to include drugs absorbed in amounts
"sufficiently small as to have no pharmacological or toxicological signifi-
cance." 47 Fed. Reg. 54,750, 54,751 (1982). For example, OTC drugs used topi-
cally, or mouthwashes regulated as OTC drugs, (which, due to their method
of use are not intended to be systemically absorbed) will not be covered by
the new regulation. Id.
309. Id. Cosmetic products were not covered by the original proposal, nor are they
included in the final regulations. Id. at 54,752.
310. 21 C.F.R. § 201.63(d) (1982) provides for exemptions from the pregnancy-nurs-
ing general warning requirement "where appropriate" upon petition under 21
C.F.R. 10.30 (1982). For example, manufacturers who believe that available
data demonstrates that their products, although intended for systemic ab-
sorption, are safe for use by pregnant and nursing women may petition for an
exemption from the warning requirement. 21 C.F.R. § 201.63(d) (1982).
311. The FDA observed that such exemptions are reasonable "because such drugs
would have been evaluated specifically for their effects on the fetus or infant
and [would have been] demonstrated to be beneficial." 21 C.F.R. § 201.63(d)
(1982). Drugs labeled exclusively for pediatric use are also exempted "be-
cause pregnant or nursing women would not be taking such products." Id.
312. 47 Fed. Reg. at 54,751 (1982).
313. Id. at 54,752.
314. Id. at 54,754. As the FDA stated, "An implicit assumption underlying most
OTC drug labeling regulations is that consumers, in pursuing their own best
interests, will read labeling that is appropriately designed and worded." Id.
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B. The New Warning: What It Is Not
The new general warning is not an original concept on the part
of the FDA. The State of California had already approved new re-
quirements that were to become effective on November 18, 1982,
which provided for the following warning to appear on over-the-
counter drugs in that state: "Caution: If pregnant or nursing a
baby, consult your physician or pharmacist before using this prod-
uct."3 15 Fearing perhaps that California's action would lead to a
wide range of confusing or conflicting state warning labeling re-
quirements, the FDA was spurred into action to provide the uni-
form national message. The agency acknowledged once again that
warnings must be used 'Judiciously" so that they do not lose their
effectiveness.3 16 But is the twenty-four word warning the most ef-
fective one that could have been chosen? Furthermore, is criticism
of the FDA's "central assumption," that hazards can be minimized
by instructions and warnings in the labeling, relevant to those
over-the-counter drugs affected by the new regulations?
1. Other Suggested Warnings
On September 7, 1982, the FDA invited interested persons to file
written comments regarding the proposed new rules (due on or
before October 7, 1982). The alternative warnings received suggest
the diverse interests that responded.3 17 One commentator pro-
posed that the following language precede the warning: "CAU-
TION: This drug has not been proven safe for babies before or
315. Id. at 54,750. The FDA reiterated that a single national pregnancy-nursing
warning with a specified text is necessary to ensure that OTC drugs are used
safely and for their intended purposes. Id. at 54,756. "A single national warn-
ing will help ensure that consumers receive clear, unambiguous, and consis-
tent information on the labeling of OTC drugs concerning use by pregnant or
nursing women." Id.
316. Id. at 54,753.
317. In response to the invitation for written comments about the proposed regu-
lations, the FDA received comments from 19 drug manufacturers, two drug
merchandisers, 11 health professional associations, five women's organiza-
tions, three state governments, 14 private individuals, and four consumer as-
sociations. Id. at 54,750. The comments reflect this "diversity". For example,
one commentator stated that the FDA did not provide studies to show that
the general warning will actually cause women to consult with health profes-
sionals before using OTC drugs. 'The implication was that the warning
should not, therefore, be required." Id. at 54,754 (emphasis added). Another
contended that the general warning undermines the very concept of an OTC
drug as one that can be used in the treatment of illnesses and disorders as
diagnosed by the lay person. Id. at 54,755. Finally, it was contended that to
the extent the general warning would encourage physician consultation for
every set of symptoms experienced, it [the warning] could seriously disrupt
the delicate balance that now exists in our nation's health care system. Id.
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after birth."318 The commentator further argued that the proposed
warning statement failed to convey the most essential message:
"that the risks of taking certain OTC drugs during pregnancy and
nursing are either unknown or known to be dangerous."
3 19
Another commentator stated that the proposed warning needed
to be strengthened and suggested that the following statement pre-
cede the warning: "USAGE IN PREGNANCY: The effect of this
drug on the fetus and/or the subsequent development of the ex-
posed offspring is unknown."3 20 Another response observed that
the FDA's proposed warning lacked grammatical preciseness and
suggested the following alternative warning: "If you are pregnant
or nursing a baby, you should seek professional advice before us-
ing this or any other drug product."3 21 The proposed rule was also
criticized for placing full responsibility "to discern the possible
existence of harmful effects on the woman whose fetus is at
risk .... "322 The following alternative was offered: "If pregnant or
nursing an infant, do not use this product without consulting a
health professional."323 The argument was raised that the pro-
posed general warning would have absolutely no impact on the
many women in this country who cannot read.324 The FDA noted
that in addition to the written warning, properly designed symbols
could be used to attract the attention of those women. However,
the agency refused to make such a symbol mandatory, stating that
it would "permit voluntary use of such symbols by manufactur-
ers. '3 25 This defacto rejection by the agency contradicts in part the
FDA's own language that "[a]n explicit assumption underlying
most OTC drug labeling regulations is that consumers, in pursuing
their own best interests, will read labeling that is appropriately
designed and worded."326
318. Id. at 54,753.
319. Id.
320. Id.
321. Id.
322. Id. at 54,751.
323. Id.
324. Id. at 54,753.
325. Id.
326. Id. at 54,754.
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Proposed symbol: 27
2. Will the Warning Be Heeded?
Several commentators have observed that if the general warn-
ing is used when it is not necessary (e.g., on all systemically ab-
sorbed over-the-counter drugs) it would "dilute" the impact of
important cautionary statements. 328 Another commentator has
contended that the general warning would "join other phrases that
are so ubiquitous they are not read."329 Two of the best examples
of warnings that go unread or unheeded by millions of American
consumers each day are the saccharin warning: "Use of this prod-
uct may be hazardous to your health. This product contains
saccharin which has been determined to cause cancer in labora-
tory animals,"330 and the warning that appears on all cigarette
packaging and advertising: "Warning- The Surgeon General Has
Determined That Cigarette Smoking Is Dangerous to Your
Health."31 In the case of saccharin, the safety of this chemical
was bitterly contested during the first five years after the enact-
ment of the 1906 Act!332 The controversy continues today, over
seventy-five years later. The case of the ineffectiveness of ciga-
rette warnings is certainly difficult to dismiss. Recently, a Reagan
administration official endorsed the idea of having even tougher
warnings for cigarettes.3 33 Currently, a bill is being proposed that
would require the use of three different warnings on a rotating
basis:
327. Id. at 54,753.
328. Id.
329. Id.
330. This warning uniformly appears on millions of soft drink cans, bottles, and
other assorted food containers.
331. The warning on packaging and advertising as it has appeared for the last two
decades.
332. Hutt, supra note 92, at 131.
333. Health Official Endorses Move For Tougher Cigarette Warnings, Omaha
World Herald, March 10, 1983, at 25, coL 3 [hereinafter cited as Tougher Ciga-
rette Warning ].
[Vol. 62:526
DRUGS DURING PREGNANCY
Warning: Cigarette-smoking causes lung cancer and emphysema, is a ma-
jor cause of heart disease, is addictive and may result in death.
Warning. Cigarette-smoking by pregnant women may result in miscar-
riage, premature births or birth weight deficiencies.
Smokers: No matter how long you have smoked, quitting now greatly
reduces the risks to your health.334
But Americans smoked 634 billion cigarettes last year, despite the
current warning.33 5 Dr. Edward Brandt Jr., assistant secretary of
health, testified to a House subcommittee that, "[s]moking re-
mains the major cause of premature death and disability," adding
that "[i]t is well established that cigarette smoking is a drug de-
pendence and that cigarette smoking is addictive to many peo-
ple."3 36 A new Government pamphlet asserts that cigarette
smoking is not just a habit, but represents the most widespread
example of drug dependence in this country, with 56 million Amer-
icans presently smoking.337 However, Reginald Lester, a spokes-
man for the Tobacco Growers Information Committee, stated that
he was not surprised that the government was not telling the true
story: "It's quite an overstatement. There are no studies in exist-
ence which can prove a causal link between cigarettes and any dis-
ease."338 He further stated, "Ninety percent of all smokers already
believe there could be a link, so continued government expendi-
tures for pamphlets like this are wasteful and ridiculous."3 39 It
would indeed be difficult to imagine a successful cause of action by
a plaintiff who claimed to have developed health problems as a re-
sult of smoking cigarettes, given the current warnings. In a similar
way, the manufacturers of the numerous over-the-counter drugs
bearing the new label warnings can perhaps successfully defend
against subsequent consumer claims of injury to their offspring or
themselves. This may or may not be an unwelcome side effect of
the labeling regulations.
VI. CONCLUSION
The credibility of regulatory agencies has been severely dam-
aged by the mounting evidence, as the result of one form of scien-
tific test or another, that indicates that some of the most popular
items in our food supply are carcinogenic. As one commentator
asserted, "The public is not prepared to give up charcoal-broiled
334. Id.
335. USDA: Americans Smoked Less in 1982 Omaha World Herald, March 10, 1983,
at 25, col. 4.
336. Tougher Cigarette Warning, supra note 333.
337. Smoking Called Worst Drug Dependency, Omaha World Herald, March 7,
1983, at 1, col. 2.
338. Id. at cols. 3 & 4.
339. Id. at coL 4.
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steak or hamburgers, pepper, nutmeg, mustard, and coffee, much
less the essential nutrients that have been implicated by this sci-
entific evidence."340 As a group, American consumers are often
willing to accept long-term risk on a voluntary basis if short-term
benefits can be derived in the process. The examples of saccharin
and cigarettes are indicative of this fact.3 4 ' But in terms of a life-
time, the tragic reality for a newborn baby damaged as the result of
drugs taken by its mother is not a long-term risk, rather, it is an
immediate one. Pregnant and nursing women are far too willing to
ingest a variety of chemicals which are potentially harmful to their
offspring, often erroneously assuming that because the drug can be
purchased without a prescription, it must indeed be safe.
Whether the new general warnings on the labels of thousands
of over-the-counter drugs go the way of the cigarette and saccharin
warnings (and are likewise generally ignored) depends upon the
actions of both the government and the drug industry in providing
more complete information and better education for the American
consumer. After all, if there is even a chance of injury, it is the
consumer and not the drug company who should have the opportu-
nity of evaluating the risk involved in taking the drug.
As has happened so often in the past, the government has
finally taken a step in the right direction but has again stopped
short. The new labeling requirement should provide, in addition to
the warning, a symbol that will insure that the thousands of illiter-
ate women may also be warned. This warning symbol should be
made mandatory if the drug manufacturers do not voluntarily in-
clude it. If the present language of the warnings proves to be
either unclear or ineffective, the warning should be revised and
strengthened based upon feedback from consumers using the af-
fected products. Finally, large scale public education campaigns
informing consumers about the uses of all drugs during pregnancy
should be considered by government and industry "working as
partners" -2 to protect the unborn American consumer.
David DeTar Newbert '83
340. Hutt, supra note 92, at 129.
341. Id. See supra notes 331-40 and accompanying text.
342. See supra note 213 and accompanying text.
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